5,430 results on '"Pneumococcal conjugate vaccine"'
Search Results
2. Factors affecting the antimicrobial changes during treatment for acute otitis media in Japan: A retrospective cohort study using classification and regression trees (CART) analysis.
- Author
-
Kono, Masamitsu, Murakami, Daichi, Sakatani, Hideki, Okuda, Katsuya, Kinoshita, Tetsuya, Hijiya, Masayoshi, Iyo, Takuro, Shiga, Tatsuya, Morita, Yohei, Itahashi, Koju, Sasagawa, Yuji, Iwama, Yasuhiro, Yamaguchi, Tomohisa, and Hotomi, Muneki
- Subjects
- *
ACUTE otitis media , *REGRESSION trees , *OTITIS media , *MEDICAL record databases , *HEALTH facilities , *ELECTRONIC health records - Abstract
Factors that affect the change of first-line antimicrobial agents were investigated to further promote their appropriate use. This descriptive study used an electronic medical records database. Total 16,353 of the 199,896 patients enrolled between 1996 and 2019 met the inclusion criteria and formed the overall pediatric acute otitis media (AOM) cohort. The factors leading to the change in first-line antimicrobial agents within 14 days were analyzed using classification and regression trees (CART) analysis. This antimicrobial treatment cohort, involved 4860 cases of AOM alone and 9567 cases of AOM with other diseases. The size of the medical facility based on number of beds and historical duration of patient registration impacted on antimicrobial changes. The current results show that hospital-wide or nation-wide antimicrobial stewardship promotion could be the most influencing factor for antimicrobial changes. Particularly in cases of AOM where other diseases coexist, a more accurate diagnosis and definition of treatment failure of first-line drug are suggested to be important while establishing future treatment strategies. The current study is important to promote appropriate antimicrobial use for AOM treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Multicentre case–control study of pneumococcal infections among children with pneumonia in Peninsular Malaysia (MY-Pneumo): a study protocol.
- Author
-
Ramzi, Nurul Hanis, Hoong, Andrew Tan Chun, Johari, Nur Alia, Nathan, Anna Marie, Teh, Cindy Shuan Ju, Sulaiman, Norhayati Aida, Ilias, Mohamad Ikram, Deris, Zakuan Zainy, Hazlan, Siti Nur Haidar, Nasir, Nur Syafiqah Mohamad, Bakar, Asrar Abu, Helmi, Muhd Alwi Muhd, Juhari, Wan Khairunnisa Wan, Kamarudin, Norhidayah, Chong, Chun Wie, Cleary, David W., Clarke, Stuart C., and Sulaiman, Lokman Hakim
- Subjects
- *
PNEUMOCOCCAL pneumonia , *STREPTOCOCCAL diseases , *DATA structures , *STREPTOCOCCUS pneumoniae , *INSTITUTIONAL review boards - Abstract
Background: S. pneumoniae (SPN) is the most common cause of pneumonia. The disease can be effectively prevented through immunisation. Since December 2020, the Malaysian Government has included the 10-valent pneumococcal conjugate vaccine (PCV10) for all infants born on or after 1 January 2020 as part of the National Immunisation Programme (NIP). However, the epidemiology of pneumonia remains poorly understood. To fill the knowledge gap, we established a multicentre surveillance study to understand the burden of pneumococcal pneumonia among young children in Peninsular Malaysia. Methods: MY-Pneumo is a multicentre prospective case–control study conducted in three sentinel sites located in three different states of Peninsular Malaysia – Kuala Lumpur, Pahang, and Kelantan. A cohort of at least 500 incident cases and 500 controls is enrolled beginning in October 2021 and matched for age. Cases are hospitalised children < 5 years with radiologically confirmed pneumonia, and the controls are children without any features suggestive of pneumonia. Clinical samples, including nasopharyngeal swabs (NPS) and urine, are collected according to the study protocol. Biological fluids such as blood, cerebrospinal fluid (CSF) and pleural fluid are obtained from invasive pneumonia disease (IPD) patients, if available. All children are tested for SPN using polymerase chain reaction (PCR) and pneumococcal urine antigen test (PUAT) using BinaxNow. Discussion: Surveillance data, including carriage rate, serotype variations and the phylogeny data structure of SPN among young children in Malaysia during PCV implementation, will be generated from this study. Trends and patterns of pneumococcal serotypes by different regions are important for targeted public health strategies. Our data will provide baseline information for estimating the impact of PCV10 implementation and will influence policymakers' decisions regarding the upgrade from PCV10 to a higher-valency conjugate vaccine in Malaysia. Trial registration: This project was registered at ClinicalTrials.gov (NCT04923035) on 2021, June 11. The study protocol was approved by the International Medical University Joint-Committee on Research & Ethics (4.15/JCM-216/2021) and the Institutional Review Board at sentinel sites (USM/JEPeM/21020190, IREC 2021–114, MREC ID No: 2021128–9769) and University of Southampton's Ethics and Research Governance (ERGo II 64844). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. How common is otogenic meningitis? A retrospective study in southern Sweden over 18 years.
- Author
-
Bjar, Nora, Hermansson, Ann, and Gisselsson-Solen, Marie
- Subjects
OTITIS media ,RISK assessment ,BACTERIAL meningitis ,DEATH ,MENINGITIS ,TREATMENT effectiveness ,HOSPITALS ,DESCRIPTIVE statistics ,NEISSERIA ,STREPTOCOCCUS ,PNEUMOCOCCAL vaccines ,MEDICAL records ,ACQUISITION of data ,OTOSCOPY ,DISEASE risk factors ,DISEASE complications - Abstract
Background: Bacterial meningitis is a rare, but life-threatening disease, which sometimes occurs as a complication to acute otitis media (AOM). The proportion of meningitis cases originating from AOM is not clear. Purpose: The aim of this study was to investigate the proportion of meningitis cases caused by AOM, to compare risk factors, bacteriology and outcome between otogenic and non-otogenic meningitis, and to analyse the incidence of bacterial meningitis after the introduction of conjugate pneumococcal vaccines (PCV). Methods: The medical charts of all patients admitted to hospitals in southern Sweden with bacterial meningitis between 2000 and 2017 were retrieved. Based on otoscopy and/or imaging, the proportion of otogenic meningitis cases was calculated, as were annual incidences. Results: A total of 216 patients were identified, 25 of whom died. The proportion of otogenic meningitis was 31% but varied from 6% among teenagers to 40% among adults. Before PCV, 23% of all meningitis cases were children < 2 years, compared to 1% post-PCV. The average incidence in the adult population, on the other hand, increased post-PCV, though there were large annual variations. S. pneumoniae was the most commonly identified pathogen in everyone but teenagers, in whom N. meningitidis was predominant. Conclusion: AOM is an important cause of meningitis in children and adults. Though bacterial meningitis almost disappeared in children < 2 years after the introduction of PCV, the incidence of pneumococcal meningitis in adults seems to have increased. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010.
- Author
-
Uraguchi, Kensuke, Matsumoto, Naomi, Mitsuhashi, Toshiharu, Takao, Soshi, Makihara, Seiichiro, Ando, Mizuo, and Yorifuji, Takashi
- Subjects
- *
OTITIS media , *PEDIATRIC respiratory diseases , *LONGITUDINAL method , *POISSON regression , *PNEUMOCOCCAL vaccines , *VACCINE safety - Abstract
• Japan's first long-term nationwide study on pediatric OM: 2001 and 2010 cohorts. • Infantile OM annual period prevalence: notable difference between 2001 and 2010 cohorts. • 9.7% OM relative risk reduction between the ages of 4.5 and 5.5 in 2010 cohort (post-PCV7). Otitis media (OM) is a prevalent respiratory disease in children and poses significant public health challenges due to its impact on child health and economic burdens. However, there have no nationwide epidemiological studies conducted in Japan. This study investigates the epidemiological trends of OM in Japan, taking into account the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) introduction. This study was retrospective cohort study using secondary data on the nationwide longitudinal birth cohort. This survey followed two cohorts born in 2001 (pre-PCV era) and 2010 (post-PCV era) until the age of 9. Every year, parents were surveyed about their children's health status, including occurrences of OM. The annual period prevalence and cumulative incidence of OM were assessed in this study, and the two cohorts were compared using a modified Poisson regression model adjusted environmental factors with the 2001 cohort as reference. The study included 47,015 children from the 2001 cohort and 38,554 from the 2010 cohort. Peak annual period prevalence of OM varied by era. Cumulative incidence was 13.8 % for the 2001 cohort and 18.5 % for the 2010 cohort by 1.5 years of age and 28.9 % and 33.3 %, respectively, by 3.5 years of age. In particular, from the fourth survey onward, covering ages 2.5–3.5 years, a shift was observed from an increased risk to a decreased risk of OM. This nationwide longitudinal study emphasizes variations in OM epidemiology across Japan over time, with changes potentially influenced by the introduction of PCV7. In this study, due to the absence of individual PCV7 vaccination data, the effect of PCV7 was estimated based on the vaccination rate at the population level. The results suggest a notable decrease in the incidence of OM in later years, aligning with the increased uptake of PCV7. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
- Author
-
Kandasamy, Rama, Gurung, Meeru, Shrestha, Sonu, Gautam, Madhav C., Kelly, Sarah, Thorson, Stephen, Ansari, Imran, Gould, Katherine, Hinds, Jason, Kelly, Dominic F., Murdoch, David R, Pollard, Andrew J., and Shrestha, Shrijana
- Subjects
- *
PNEUMOCOCCAL vaccines , *NEPALI people , *DENSITY , *LIFE sciences , *SEROTYPING , *BOTULINUM A toxins - Abstract
• Carriage of vaccine serotypes declined following PCV10 introduction. • Multiple-serotype carriage was reduced following PCV10 introduction. • Pneumococcal carriage density among children was lower following PCV10 introduction. Carriage studies are an efficient means for assessing pneumococcal conjugate vaccine effect in settings where pneumococcal disease surveillance programmes are not well established. In this study the effect of 10-valent pneumococcal conjugate vaccine (PCV10) introduction on pneumococcal carriage and density among Nepalese children using a bacterial microarray and qPCR was examined. PCV10 was introduced into the Nepalese infant immunisation schedule in August 2015. Nasopharyngeal swabs were collected from healthy Nepalese children in Kathmandu between April 2014 and December 2021. Samples were plated on blood agar, incubated overnight, and DNA extracted from plate sweeps. Pneumococcal serotyping was done using the Senti-SPv1.5 microarray (BUGS Bioscience, UK). DNA was extracted from swab media and qPCR performed for pneumococcal autolysin (lytA). A significant decline in prevalence of PCV10 serotypes was observed when comparing pre-PCV10 with post-PCV10 collection periods (36.5 %, 454/1244 vs 10.3 %, 243/2353, p < 0.0001). Multiple-serotype carriage was also observed to significantly decline when comparing pre-PCV10 with post-PCV10 periods (31.4 %, 390/1244 vs 22.2 %, 522/2353, p < 0.0001). Additionally, a significant decline in median pneumococcal density was observed when comparing pre-PCV10 with post-PCV10 periods (3.3 vs 3.25 log10 GE/ml, p = 0.0196). PCV10 introduction was associated with reduced, prevalence of all PCV10 serotypes, multiple serotype carriage, and pneumococcal carriage density. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
- Author
-
Kalizang'oma, Akuzike, Swarthout, Todd D, Mwalukomo, Thandie S, Kamng'ona, Arox, Brown, Comfort, Msefula, Jacquline, Demetriou, Hayley, Chan, Jia Mun, Roalfe, Lucy, Obolski, Uri, Lourenço, Jose, Goldblatt, David, Chaguza, Chrispin, French, Neil, and Heyderman, Robert S
- Subjects
- *
PNEUMOCOCCAL vaccines , *STREPTOCOCCUS pneumoniae , *WHOLE genome sequencing , *POLYSACCHARIDES , *DRUG resistance in microorganisms , *STREPTOCOCCUS - Abstract
Background Streptococcus pneumoniae serotype 3 remains a problem globally. Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2011, but there has been no direct protection against serotype 3 carriage. We explored whether vaccine escape by serotype 3 is due to clonal expansion of a lineage with a competitive advantage. Methods The distribution of serotype 3 Global Pneumococcal Sequence Clusters (GPSCs) and sequence types (STs) globally was assessed using sequences from the Global Pneumococcal Sequencing Project. Whole-genome sequences of 135 serotype 3 carriage isolates from Blantyre, Malawi (2015–2019) were analyzed. Comparative analysis of the capsule locus, entire genomes, antimicrobial resistance, and phylogenetic reconstructions were undertaken. Opsonophagocytosis was evaluated using serum samples from vaccinated adults and children. Results Serotype 3 GPSC10-ST700 isolates were most prominent in Malawi. Compared with the prototypical serotype 3 capsular polysaccharide locus sequence, 6 genes are absent, with retention of capsule polysaccharide biosynthesis. This lineage is characterized by increased antimicrobial resistance and lower susceptibility to opsonophagocytic killing. Conclusions A serotype 3 variant in Malawi has genotypic and phenotypic characteristics that could enhance vaccine escape and clonal expansion after post-PCV13 introduction. Genomic surveillance among high-burden populations is essential to improve the effectiveness of next-generation pneumococcal vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Immunogenicity, Immunological Memory and Monitoring of Disease Activity Following an Anamnestic Immunization With the 13-Valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome.
- Author
-
Kitsou, Konstantina, Askiti, Varvara, Tzanoudaki, Marianna, Mitsioni, Andromachi, Papadatou, Ioanna, Liatsis, Emmanouil, Kanaka-Gantenbein, Christina, Magiorkinis, Gkikas, and Spoulou, Vana
- Subjects
- *
STREPTOCOCCAL disease prevention , *ADRENOCORTICAL hormones , *RESEARCH funding , *SEROTYPING , *NEPHROTIC syndrome , *PNEUMOCOCCAL vaccines , *VACCINE immunogenicity , *STREPTOCOCCAL diseases , *B cells , *IMMUNOMODULATORS , *CHILDREN - Abstract
Anamnestic 13-valent pneumococcal conjugate vaccine immunization did not affect the relapse risk in pediatric idiopathic nephrotic syndrome. Pneumococcal serotype (PS)-specific antibody titers increased significantly in all groups. Children receiving immunomodulatory treatments (IMTs) displayed significantly lower levels of PS-specific antibodies for 3/8 serotypes tested. PS-specific B-cell counts significantly increased only in healthy controls and patients receiving corticosteroids. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States.
- Author
-
Yi, Zinan, Johnson, Kelly D., and Owusu-Edusei, Kwame
- Subjects
- *
SEROTYPES , *ADULTS , *PNEUMOCOCCAL vaccines , *MARKOV processes , *DIRECT costing , *PNEUMOCOCCAL meningitis - Abstract
Introduction: This study aimed to estimate and compare the lifetime clinical and economic burden of invasive pneumococcal diseases (IPD) attributable to the serotypes contained in a new 21-valent pneumococcal conjugate vaccine (V116) vs. the 20-valent pneumococcal conjugate vaccine (PCV20) among adults aged 18 years and above in the USA. Methods: A state-transition Markov model was used to track IPD cases and deaths as well as the associated direct medical costs (in 2023 US dollars) from a US healthcare payer perspective at 3% annual discount rate. The results were summarized for V116, PCV20, and eight unique serotypes contained in V116. A sensitivity analysis was conducted to determine the most influential inputs on the overall total direct lifetime cost. Results: For the total population of US adults aged 18 years and above in 2021 (approx. 258 million residents), the estimated lifetime numbers of cases of IPD, post-meningitis sequelae (PMS), and IPD-related deaths attributable to the serotypes contained in V116 were approximately 1.4 million, 17,608, and 186,200, respectively, with a total discounted lifetime direct cost of $32.6 billion. A substantial proportion (approx. 31%) of those were attributable to the unique eight serotypes. The corresponding estimates for PCV20 were approximately 35% lower—934,000, 11,500, and 120,000, respectively—with a total discounted direct lifetime cost of $21.9 billion. Conclusion: These results show that V116 serotypes (compared to PCV20) are associated with substantially higher clinical and economic burden of IPD. The addition of V116 to vaccination recommendations can help to reduce the residual burden of IPD in US adults. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Multicentre case–control study of pneumococcal infections among children with pneumonia in Peninsular Malaysia (MY-Pneumo): a study protocol
- Author
-
Nurul Hanis Ramzi, Andrew Tan Chun Hoong, Nur Alia Johari, Anna Marie Nathan, Cindy Shuan Ju Teh, Norhayati Aida Sulaiman, Mohamad Ikram Ilias, Zakuan Zainy Deris, Siti Nur Haidar Hazlan, Nur Syafiqah Mohamad Nasir, Asrar Abu Bakar, Muhd Alwi Muhd Helmi, Wan Khairunnisa Wan Juhari, Norhidayah Kamarudin, Chun Wie Chong, David W. Cleary, Stuart C. Clarke, and Lokman Hakim Sulaiman
- Subjects
Streptococcus pneumoniae ,Pneumococcal Pneumonia ,Pneumonia Childhood ,Invasive Pneumonia Disease ,Pneumococcal conjugate vaccine ,Surveillance ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background S. pneumoniae (SPN) is the most common cause of pneumonia. The disease can be effectively prevented through immunisation. Since December 2020, the Malaysian Government has included the 10-valent pneumococcal conjugate vaccine (PCV10) for all infants born on or after 1 January 2020 as part of the National Immunisation Programme (NIP). However, the epidemiology of pneumonia remains poorly understood. To fill the knowledge gap, we established a multicentre surveillance study to understand the burden of pneumococcal pneumonia among young children in Peninsular Malaysia. Methods MY-Pneumo is a multicentre prospective case–control study conducted in three sentinel sites located in three different states of Peninsular Malaysia – Kuala Lumpur, Pahang, and Kelantan. A cohort of at least 500 incident cases and 500 controls is enrolled beginning in October 2021 and matched for age. Cases are hospitalised children
- Published
- 2024
- Full Text
- View/download PDF
11. PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
- Author
-
Timothy J Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston, Gretchen Tamms, Robert Lupinacci, Kristen Feemster, Ulrike K Buchwald, and Natalie Banniettis
- Subjects
Immunogenicity ,PCV15 ,pediatric ,phase 3 ,pneumococcal conjugate vaccine ,pneumonia ,Internal medicine ,RC31-1245 - Abstract
ABSTRACTIntroduction Streptococcus pneumoniae is a causative agent of pneumonia and acute otitis media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 (V114) is a new 15-valent pneumococcal conjugate vaccine (PCV) approved for use in individuals ≥6 weeks of age for the prevention of pneumonia, AOM, and invasive pneumococcal disease.Areas Covered This review summarizes the V114 Phase 3 development program leading to approval in infants and children, including pivotal studies, interchangeability and catch-up vaccination studies, and studies in at-risk populations. An integrated safety summary is presented in addition to immunogenicity and concomitant use of V114 with other routine pediatric vaccines.Expert Opinion Across the development program, V114 demonstrated a safety profile that is comparable to PCV13 in infants and children. Immunogenicity of V114 is comparable to PCV13 for all shared serotypes except serotype 3, where V114 demonstrated superior immunogenicity. Higher immune responses were demonstrated for V114 serotypes 22F and 33F. Results of the ongoing study to evaluate V114 efficacy against vaccine-type pneumococcal AOM and anticipated real-world evidence studies will support assessment of vaccine effectiveness and impact, with an additional question of whether higher serotype 3 immunogenicity translates to better protection against serotype 3 pneumococcal disease.
- Published
- 2024
- Full Text
- View/download PDF
12. Invasive Pneumococcal Disease Study
- Author
-
Pfizer
- Published
- 2023
13. Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States
- Author
-
Zinan Yi, Kelly D. Johnson, and Kwame Owusu-Edusei
- Subjects
Invasive pneumococcal disease ,Pneumococcal conjugate vaccine ,Markov model ,Health and economic burden ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction This study aimed to estimate and compare the lifetime clinical and economic burden of invasive pneumococcal diseases (IPD) attributable to the serotypes contained in a new 21-valent pneumococcal conjugate vaccine (V116) vs. the 20-valent pneumococcal conjugate vaccine (PCV20) among adults aged 18 years and above in the USA. Methods A state-transition Markov model was used to track IPD cases and deaths as well as the associated direct medical costs (in 2023 US dollars) from a US healthcare payer perspective at 3% annual discount rate. The results were summarized for V116, PCV20, and eight unique serotypes contained in V116. A sensitivity analysis was conducted to determine the most influential inputs on the overall total direct lifetime cost. Results For the total population of US adults aged 18 years and above in 2021 (approx. 258 million residents), the estimated lifetime numbers of cases of IPD, post-meningitis sequelae (PMS), and IPD-related deaths attributable to the serotypes contained in V116 were approximately 1.4 million, 17,608, and 186,200, respectively, with a total discounted lifetime direct cost of $32.6 billion. A substantial proportion (approx. 31%) of those were attributable to the unique eight serotypes. The corresponding estimates for PCV20 were approximately 35% lower—934,000, 11,500, and 120,000, respectively—with a total discounted direct lifetime cost of $21.9 billion. Conclusion These results show that V116 serotypes (compared to PCV20) are associated with substantially higher clinical and economic burden of IPD. The addition of V116 to vaccination recommendations can help to reduce the residual burden of IPD in US adults.
- Published
- 2024
- Full Text
- View/download PDF
14. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis
- Author
-
An Ta, Felicitas Kühne, Maren Laurenz, Christof von Eiff, Sophie Warren, and Johnna Perdrizet
- Subjects
Pneumococcal disease ,Cost-effectiveness ,Pneumococcal conjugate vaccine ,Pediatric, invasive pneumococcal disease, pneumonia, otitis media ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany’s Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared 20-valent PCV (PCV20) under a 3+1 schedule with 15-valent PCV (PCV15) and PCV13, both under 2+1 schedule, in Germany’s pediatric population. Methods A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic impact of pediatric vaccination with PCV20 versus lower-valent PCVs in Germany. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Conclusion PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20’s broader serotype coverage.
- Published
- 2024
- Full Text
- View/download PDF
15. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
- Author
-
Lucila Rey-Ares, Ahuva Averin, Mercedes Mac Mullen, Dhwani Hariharan, Mark Atwood, Carolina Carballo, and Liping Huang
- Subjects
Streptococcus pneumoniae ,Vaccination ,Pneumococcal conjugate vaccine ,Cost-effectiveness ,Argentina ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction In Argentina, vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23; PCV13 → PPSV23) has been recommended for all adults aged ≥ 65 years and younger adults with chronic medical (“moderate-risk”) or immunocompromising (“high-risk”) conditions since 2017. With the approval of a 20-valent PCV (PCV20), we evaluated the cost-effectiveness of PCV20 versus current recommendations for moderate-/high-risk adults aged 18–64 years and all adults 65–99 years. Methods A probabilistic cohort model was used to project lifetime outcomes and costs associated with invasive pneumococcal disease (IPD) and all-cause non-bacteremic pneumonia (NBP), and the expected impact of vaccination. Clinical outcomes were projected annually based on Argentinean data. Economic costs were estimated based on cases and corresponding medical costs (adjusted to 2023 USD) and costs of vaccine and administration. Cost-effectiveness of PCV20 was evaluated versus the current strategy, PCV13 → PPSV23, and alternatively, versus sequentially administered 15-valent PCV and PPSV23 (PCV15 → PPSV23), and presented as cost per quality-adjusted life year gained; a healthcare system perspective was used. Costs and benefits were discounted at 3%/year. Results PCV20 in lieu of PCV13 → PPSV23 among moderate-/high-risk adults aged 18–64 years and all adults 65–99 years (N = 13.4M) prevented 3838 IPD, 4377 inpatient NBP, and 6003 outpatient NBP cases, and 1865 disease-related deaths; relative to PCV15 → PPSV23 the corresponding reductions were 2775, 3285, 4518, and 1348. PCV20 was projected to be the dominant strategy versus PCV13 → PPSV23 and PCV15 → PPSV23 as overall costs were lower by $87.6M and $80.8M, respectively. In probabilistic sensitivity analyses, PCV20 was dominant (i.e., more effective, less costly) in 100% of 1000 simulations. Conclusions Analyses suggest implementing a PCV20 vaccination program in moderate-/high-risk adults aged 18–64 years and all adults ≥ 65 years—in lieu of PCV13 → PPSV23—would yield substantial reductions in pneumococcal disease and would be cost saving to the Argentinean healthcare system.
- Published
- 2024
- Full Text
- View/download PDF
16. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
- Author
-
Rey-Ares, Lucila, Averin, Ahuva, Mac Mullen, Mercedes, Hariharan, Dhwani, Atwood, Mark, Carballo, Carolina, and Huang, Liping
- Subjects
- *
PNEUMOCOCCAL vaccines , *MENINGOCOCCAL infections , *ADULTS , *OLDER people , *PNEUMOCOCCAL pneumonia , *QUALITY-adjusted life years , *PNEUMOCOCCAL meningitis - Abstract
Introduction: In Argentina, vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23; PCV13 → PPSV23) has been recommended for all adults aged ≥ 65 years and younger adults with chronic medical ("moderate-risk") or immunocompromising ("high-risk") conditions since 2017. With the approval of a 20-valent PCV (PCV20), we evaluated the cost-effectiveness of PCV20 versus current recommendations for moderate-/high-risk adults aged 18–64 years and all adults 65–99 years. Methods: A probabilistic cohort model was used to project lifetime outcomes and costs associated with invasive pneumococcal disease (IPD) and all-cause non-bacteremic pneumonia (NBP), and the expected impact of vaccination. Clinical outcomes were projected annually based on Argentinean data. Economic costs were estimated based on cases and corresponding medical costs (adjusted to 2023 USD) and costs of vaccine and administration. Cost-effectiveness of PCV20 was evaluated versus the current strategy, PCV13 → PPSV23, and alternatively, versus sequentially administered 15-valent PCV and PPSV23 (PCV15 → PPSV23), and presented as cost per quality-adjusted life year gained; a healthcare system perspective was used. Costs and benefits were discounted at 3%/year. Results: PCV20 in lieu of PCV13 → PPSV23 among moderate-/high-risk adults aged 18–64 years and all adults 65–99 years (N = 13.4M) prevented 3838 IPD, 4377 inpatient NBP, and 6003 outpatient NBP cases, and 1865 disease-related deaths; relative to PCV15 → PPSV23 the corresponding reductions were 2775, 3285, 4518, and 1348. PCV20 was projected to be the dominant strategy versus PCV13 → PPSV23 and PCV15 → PPSV23 as overall costs were lower by $87.6M and $80.8M, respectively. In probabilistic sensitivity analyses, PCV20 was dominant (i.e., more effective, less costly) in 100% of 1000 simulations. Conclusions: Analyses suggest implementing a PCV20 vaccination program in moderate-/high-risk adults aged 18–64 years and all adults ≥ 65 years—in lieu of PCV13 → PPSV23—would yield substantial reductions in pneumococcal disease and would be cost saving to the Argentinean healthcare system. Plain Language Summary: Pneumococcal pneumonia has a high disease burden in both children and adults. Older adults and those with certain underlying conditions are more susceptible to severe pneumococcal disease resulting in considerable economic burden on the healthcare system. In Argentina, vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) a year later is recommended for all adults aged ≥ 65 years and adults aged 18–64 years with underlying risk conditions. Despite vaccination efforts, prevalence of pneumococcal disease remains high. Two higher-valent PCVs—15-valent PCV (PCV15) and 20-valent PCV (PCV20)—are available for use in adults with PCV20 offering additional serotype coverage. This study assessed the cost-effectiveness of replacing current (PCV13 → PPSV23) and alternative (PCV15 → PPSV23) vaccination strategies with PCV20 alone. The use of PCV20 was evaluated among Argentinean adults aged 18–64 years with underlying risk conditions and all adults aged 65–99 years (N = 13 million). Over a lifetime time horizon, compared to PCV13 → PPSV23, PCV20 use would avert 14,218 cases and 1865 deaths, and increase quality-adjusted life years by 8655. Compared to PCV15 → PPSV23, PCV20 reduced cases and deaths by 10,578 and 1348, respectively, and increased quality-adjusted life years by 6341. In both comparisons, PCV20 use was cost saving with $87.6 million and $80.8 million lower costs compared to PCV13 → PPSV23 and PCV15 → PPSV23, respectively. Results of the cost-effectiveness analyses suggest that the use of PCV20 is a cost-saving strategy, reducing overall costs to the healthcare system and improving public health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
- Author
-
Ta, An, Kühne, Felicitas, Laurenz, Maren, von Eiff, Christof, Warren, Sophie, and Perdrizet, Johnna
- Subjects
- *
CHILD patients , *OTITIS media , *BOOSTER vaccines , *VACCINATION of children , *PNEUMOCOCCAL vaccines , *CHILD mortality - Abstract
Introduction: Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany's Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared 20-valent PCV (PCV20) under a 3+1 schedule with 15-valent PCV (PCV15) and PCV13, both under 2+1 schedule, in Germany's pediatric population. Methods: A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic impact of pediatric vaccination with PCV20 versus lower-valent PCVs in Germany. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results: In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Conclusion: PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20's broader serotype coverage. Plain Language Summary: Pneumococcal diseases (e.g., ear infections, pneumonia, bloodstream infections) are among the leading causes of illness and death in children worldwide. The pneumococcal conjugate vaccine protects against pneumococcal diseases and has significantly reduced the number of newly diagnosed cases. Higher-valent vaccines (which provide coverage for a greater number of disease-causing serotypes) have recently received European Commission approval for use in adults and children. This study examined costs and health benefits associated with the 20-valent pneumococcal conjugate vaccine (PCV20) under a 3+1 (i.e., three primary doses and one booster dose) schedule in Germany's childhood vaccination program compared with 13-valent pneumococcal conjugate vaccine (PCV13) and the 15-valent pneumococcal conjugate vaccine (PCV15), both under a 2+1 (two primary doses, one booster) schedule. PCV20 was estimated to result in greater health benefits from avoiding more cases in pneumococcal diseases and lower costs compared with both PCV13 and PCV15. PCV20, therefore, is considered the best option among the three vaccines for children in Germany. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones.
- Author
-
Mutsaerts, E.A.M.L., van Cranenbroek, B., Madhi, S.A., Simonetti, E., Arns, A.J., Jose, L., Koen, A., van Herwaarden, A.E., de Jonge, M.I., and Verhagen, L.M.
- Subjects
- *
B cells , *NUTRITIONAL status , *BOOSTER vaccines , *VACCINE effectiveness , *MEASLES vaccines , *VACCINATION status , *DOSE-response relationship (Radiation) - Abstract
• Underweight children had decreased antibody response after pneumococcal vaccination. • Specific B-cell subsets were associated with pneumococcal antibody decay. • B-cells, metabolic hormones and nutritional status correlated with vaccine response. We explored the role of metabolic hormones and the B-cell repertoire in the association between nutritional status and vaccine responses. In this prospective cohort study, nested within a larger randomized open-label trial, 211 South African children received two doses of measles vaccine and two or three doses of pneumococcal conjugate vaccine (PCV). Metabolic markers (leptin, ghrelin and adiponectin) and distribution of B-cell subsets (n = 106) were assessed at 18 months of age. Children with a weight-for-height z-score (WHZ) ≤ −1 standard deviation (SD) at booster vaccination had a decreased mean serotype-specific PCV IgG response compared with those with WHZ > −1 and <+1 SD or WHZ ≥ +1 SD at 9 months post-booster (18 months of age). (Naive) pre-germinal center B-cells were associated with pneumococcal antibody decay between one to nine months post-booster. Predictive performance of elastic net models for the combined effect of B-cell subsets, metabolic hormones and nutritional status (in addition to age, sex, and randomization group) on measles and PCV vaccine response had an average area under the receiver operating curve of 0.9 and 0.7, respectively. The combined effect of B-cell subsets, metabolic hormones and nutritional status correlated well with the vaccination response for measles and most PCV serotypes. ClinicalTrials.gov registration of parent studies: NCT02943902 and NCT03330171. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Identification and Quantification of a Pneumococcal Cell Wall Polysaccharide by Antibody-Enhanced Chromatography Assay.
- Author
-
Deng, James Z., Chen, Zhifeng, Small, James, Yuan, Yue, Cox, Kara, Tang, Aimin, Roman, Jeanette, Guan, Liming, Feller, Katrina, Ansbro, Frances, and Vora, Kalpit
- Subjects
POLYSACCHARIDES ,PNEUMOCOCCAL vaccines ,CHROMATOGRAPHIC analysis ,MONOCLONAL antibodies ,IMMUNE response - Abstract
Multivalent pneumococcal vaccines have been developed successfully to combat invasive pneumococcal diseases (IPD) and reduce the associated healthcare burden. These vaccines employ pneumococcal capsular polysaccharides (PnPs), either conjugated or unconjugated, as antigens to provide serotype-specific protection. Pneumococcal capsular polysaccharides used for vaccine often contain residual levels of cell wall polysaccharides (C-Ps), which can generate a non-serotype specific immune response and complicate the desired serotype-specific immunity. Therefore, the C-P level in a pneumococcal vaccine needs to be controlled in the vaccine process and the anti C-P responses need to be dialed out in clinical assays. Currently, two types of cell-wall polysaccharide structures have been identified: a mono-phosphocholine substituted cell-wall polysaccharide C-Ps1 and a di-phosphocholine substituted C-Ps2 structure. In our effort to develop a next-generation novel pneumococcal conjugate vaccine (PCV), we have generated a monoclonal antibody (mAb) specific to cell-wall polysaccharide C-Ps2 structure. An antibody-enhanced HPLC assay (AE-HPLC) has been established for serotype-specific quantification of pneumococcal polysaccharides in our lab. With the new anti C-Ps2 mAb, we herein extend the AE-HPLC assay to the quantification and identification of C-Ps2 species in pneumococcal polysaccharides used for vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
- Author
-
Tembo, G., Mayuni, M., Kamng'ona, R., Chimgoneko, L., Chiwala, G., Sichone, S., Galafa, B., Thole, F., Mkandawire, C., Chirwa, A.E., Nsomba, E., Nkhoma, V., Ngoliwa, C., Toto, N., Makhaza, L., Muyaya, A., Kudowa, E., Henrion, M.Y.R., Dula, D., and Morton, B.
- Subjects
- *
IMMUNOGLOBULINS , *VIRAL antibodies , *ANTIBODY formation , *STREPTOCOCCUS pneumoniae , *SERUM , *IMMUNOGLOBULIN G , *ENZYME-linked immunosorbent assay , *PNEUMOCOCCAL vaccines - Abstract
Pneumococcal carriage is the primary reservoir for transmission and a prerequisite for invasive pneumococcal disease. Pneumococcal Conjugate Vaccine 13 (PCV13) showed a 62% efficacy in protection against experimental Streptococcus pneumoniae serotype 6B (Spn6B) carriage in a controlled human infection model (CHIM) of healthy Malawian adults. We, therefore, measured humoral responses to experimental challenge and PCV-13 vaccination and determined the association with protection against pneumococcal carriage. We vaccinated 204 young, healthy Malawian adults with PCV13 or placebo and nasally inoculated them with Spn6B at least four weeks post-vaccination to establish carriage. We collected peripheral blood and nasal lining fluid at baseline, 4 weeks post-vaccination (7 days pre-inoculation), 2, 7, 14 and > 1 year post-inoculation. We measured the concentration of anti-serotype 6B Capsular Polysaccharide (CPS) Immunoglobulin G (IgG) and IgA antibodies in serum and nasal lining fluid using the World Health Organization (WHO) standardised enzyme-linked immunosorbent assay (ELISA). PCV13-vaccinated adults had higher serum IgG and nasal IgG/IgA anti-Spn6B CPS-specific binding antibodies than placebo recipients 4 to 6 weeks post-vaccination, which persisted for at least a year after vaccination. Nasal challenge with Spn6B did not significantly alter serum or nasal anti-CPS IgG binding antibody titers with or without experimental pneumococcal carriage. Pre-challenge titers of PCV13-induced serum IgG and nasal IgG/IgA anti-Spn6B CPS binding antibodies did not significantly differ between those that got experimentally colonised by Spn6B compared to those that did not. This study demonstrates that despite high PCV13 efficacy against experimental Spn6B carriage in young, healthy Malawian adults, robust vaccine-induced systemic and mucosal anti-Spn6B CPS binding antibodies did not directly relate to protection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998–2019.
- Author
-
Mohanty, Salini, Done, Nicolae, Liu, Qing, Song, Yan, Wang, Travis, Gaburo, Katherine, Sarpong, Eric M., White, Meghan, Weaver, Jessica P., Signorovitch, James, and Weiss, Thomas
- Subjects
- *
AGE groups , *DISEASE incidence , *ACUTE otitis media , *CHILD health insurance , *MEDICAID , *BUSINESS insurance - Abstract
Pneumococcal disease (PD) is a major cause of morbidity and mortality among children, particularly in the youngest age groups. This study aimed to assess the incidence of PD over time by age group in young children with commercial or Medicaid coverage in the US. Episodes of invasive pneumococcal disease (IPD), all-cause pneumonia (ACP), and acute otitis media (AOM) were identified in the MarketScan® Commercial and Medicaid claims databases using diagnosis codes among children aged ≤ 48 months with confirmed date of birth (DoB), at any time during the study period (1998–2019). DoB was assigned using diagnosis codes for birth or delivery using the child's or mother's medical claims to ensure accurate age determination. Annual incidence rates (IRs) were calculated as number of disease episodes/100,000 person-years (PY) for IPD and ACP and episodes/1,000 PY for AOM, for children aged 0–6, 7–12, 12–24, and 25–48 months. Annual IPD IRs declined from 53 to 7 episodes/100,000 PY between 1998 and 2019 in commercially-insured and 58 to 9 episodes/100,000 PY between 2001 and 2019 in Medicaid-insured children. Annual ACP IRs declined from 5,600 to 3,952 episodes/100,000 PY, and from 6,706 to 4,521 episodes/100,000 PY, respectively, over these periods. In both populations, children aged 0–6 months had the highest incidence of IPD and inpatient ACP. Annual AOM IRs declined from 1,177 to 738 episodes/1,000 PY (commercially-insured) and 633 to 624 episodes/1,000 PY (Medicaid-insured), over these periods. IRs were higher in rural vs. urban areas for all disease manifestations. Incidence rates of IPD, ACP, and AOM decreased in children with commercial insurance and Medicaid coverage from 1998 to 2019. However, burden of disease remained substantial, with higher annual IRs for IPD and ACP for Medicaid-insured vs. commercially-insured children. IPD and inpatient ACP were most common in the youngest children 0–6 months old, followed by the 7–12-month age group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
- Author
-
Mackenzie, Grant A, Hossain, Ilias, Salaudeen, Rasheed, Badji, Henry, Manjang, Ahmed, Usuf, Effua, Bottomley, Christian, Greenwood, Brian, and Hill, Philip C
- Subjects
- *
PNEUMOCOCCAL vaccines , *AGE groups - Abstract
• Vaccine-type pneumococcal carriage in young and older children declined significantly following routine use of PCV in The Gambia. • Significant residual vaccine-type carriage in children. • Non-vaccine-type carriage increased in all age groups. • Significant pneumococcal transmission continues in the population. The introduction of pneumococcal conjugate vaccines (PCV) has reduced carriage of vaccine-type (VT) pneumococci in many settings. We determined the impact of The Gambia's national PCV programme on carriage of VT pneumococci in the population. Seven-valent PCV (PCV7) was introduced in August 2009 without catch-up and with doses scheduled at 2, 3, 4 months of age; it was replaced by PCV13 in May 2011. We did cross-sectional carriage surveys in 2009, 2015, and 2017 in age-stratified, population-based samples. Nasopharyngeal specimens were collected and processed according to WHO guidelines. We calculated observed and adjusted prevalence ratios (PR) of VT carriage before and after PCV introduction. We enrolled 2988, 3162, and 2709 participants in 2009, 2015, and 2017 respectively. The baseline (2009) prevalence of VT pneumococcal carriage among children aged 0–4 years was 42.6 %, which declined to 14.9 % and 17.5 % in 2015 and 2017 respectively (adjPR 0.32 [95 % CI 0.27, 0.38] and 0.38 [0.31, 0.46] respectively). VT prevalence among children aged 5–14 years was 16.6 %, 15.1 %, and 15.8 % in the three surveys (2017 vs 2009, adjPR 0.70 [0.58, 0.83]). VT prevalence among 15–44 year-olds was 6.4 %, 5.7 %, and 7.1 % in the three surveys (2017 vs 2009, adjPR 0.59 [0.46, 0.75]), while in those aged ≥ 45 years it was 4.5 %, 6.5 %, and 4.5 % respectively. Non-VT carriage increased in all age-groups. Prevalent residual serotypes were 34 and 15B (age 0–4 years), 3 and 34 (age 5–14 years), and 3 and 16F (age ≥ 15 years). Introduction of PCV was associated with reduced VT pneumococcal carriage in young, and older children, although with substantial residual prevalence. Persisting VT, and non-VT, carriage indicate significant, persistent transmission of pneumococci in the population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. The pneumococcal conjugate vaccine had a sustained effect on Swedish children 8 years after its introduction.
- Author
-
Alfvén, Tobias, Bennet, Rutger, Granath, Anna, Dennison, Sofia Hultman, and Eriksson, Margareta
- Subjects
- *
PNEUMOCOCCAL vaccines , *BACTERIAL meningitis , *PNEUMOCOCCAL meningitis , *STREPTOCOCCUS pneumoniae , *VACCINATION of children , *AGE groups , *MASTOIDITIS - Abstract
Aim: The pneumococcal conjugate vaccine, which covered seven serotypes of Streptococcus pneumoniae (PCV7), was introduced in Stockholm, Sweden, in 2007. It was replaced by a 13‐valent vaccine (PCV13) in 2011. We previously reported a decreased incidence of pneumonia and sinusitis among young children 4 years after the introduction of the PCV7. This study followed the incidence of pneumonia, sinusitis, mastoiditis and meningitis for four more years. Methods: We studied validated hospital registry data covering children up to 17 years of age, who were hospitalised in the Stockholm region from 2003 to 2016, when the child population peaked at 485 687. All 11 115 cases diagnosed with pneumonia, coded as bacterial pneumonia, sinusitis, mastoiditis, bacterial meningitis or empyema, were identified. The controls had viral pneumonia or pyelonephritis. Results: The incidence rates for children under 2 years of age hospitalised for sinusitis, mastoiditis and meningitis decreased significantly by 61%–79% during the eight‐year post‐vaccination period. Hospitalisations for bacterial pneumonia decreased by 19%–25% in the same age group. These changes were probably due to both the vaccines and changes in diagnosis routines. Conclusion: The effect of vaccination on children under 2 years of age was sustained 8 years after the introduction of the pneumococcal conjugate vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Nasopharyngeal carriage of Streptococcus pneumoniae among children aged 30 days to
- Author
-
Qianqian Du, Zhaoqiu Liu, Hongmei Wang, Yani Wang, Li Liu, Xuexia Wen, Sangjie Yu, Qingqing Ren, Elisa Gonzalez, Adriano Arguedas, Mark A. Fletcher, Kaijie Pan, Graciela Del Carmen Morales, Jikui Deng, and Kaihu Yao
- Subjects
Streptococcus pneumoniae ,nasopharyngeal carriage ,pneumococcal conjugate vaccine ,serotypes ,antimicrobial resistance ,Pediatrics ,RJ1-570 - Abstract
ObjectivesTo describe the carriage rate, serotype distribution, and antimicrobial susceptibility patterns of Streptococcus pneumoniae (S. pneumoniae) nasopharyngeal (NP) isolates among healthy children aged 30 days to
- Published
- 2024
- Full Text
- View/download PDF
25. Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis
- Author
-
Shuo Feng, Julie McLellan, Nicola Pidduck, Nia Roberts, Julian PT Higgins, Yoon Choi, Alane Izu, Mark Jit, Shabir A Madhi, Kim Mulholland, Andrew J Pollard, Simon Procter, Beth Temple, and Merryn Voysey
- Subjects
individual participant data ,cost-effectiveness ,pneumococcal conjugate vaccine ,meningitis ,meta-analysis ,nasopharyngeal carriage ,pneumonia ,pneumococcal infections ,prevnar ,randomised controlled trials ,seroefficacy ,streptococcus pneumoniae ,systematic review ,synflorix ,vaccine ,vaccination ,Medical technology ,R855-855.5 - Abstract
Background Vaccination of infants with pneumococcal conjugate vaccines is recommended by the World Health Organization. Evidence is mixed regarding the differences in immunogenicity and efficacy of the different pneumococcal vaccines. Objectives The primary objective was to compare the immunogenicity of pneumococcal conjugate vaccine-10 versus pneumococcal conjugate vaccine-13. The main secondary objective was to compare the seroefficacy of pneumococcal conjugate vaccine-10 versus pneumococcal conjugate vaccine-13. Methods We searched the Cochrane Library, EMBASE, Global Health, MEDLINE, ClinicalTrials.gov and trialsearch.who.int up to July 2022. Studies were eligible if they directly compared either pneumococcal conjugate vaccine-7, pneumococcal conjugate vaccine-10 or pneumococcal conjugate vaccine-13 in randomised trials of children under 2 years of age, and provided immunogenicity data for at least one time point. Individual participant data were requested and aggregate data used otherwise. Outcomes included the geometric mean ratio of serotype-specific immunoglobulin G and the relative risk of seroinfection. Seroinfection was defined for each individual as a rise in antibody between the post-primary vaccination series time point and the booster dose, evidence of presumed subclinical infection. Each trial was analysed to obtain the log of the ratio of geometric means and its standard error. The relative risk of seroinfection (‘seroefficacy’) was estimated by comparing the proportion of participants with seroinfection between vaccine groups. The log-geometric mean ratios, log-relative risks and their standard errors constituted the input data for evidence synthesis. For serotypes contained in all three vaccines, evidence could be synthesised using a network meta-analysis. For other serotypes, meta-analysis was used. Results from seroefficacy analyses were incorporated into a mathematical model of pneumococcal transmission dynamics to compare the differential impact of pneumococcal conjugate vaccine-10 and pneumococcal conjugate vaccine-13 introduction on invasive pneumococcal disease cases. The model estimated the impact of vaccine introduction over a 25-year time period and an economic evaluation was conducted. Results In total, 47 studies were eligible from 38 countries. Twenty-eight and 12 studies with data available were included in immunogenicity and seroefficacy analyses, respectively. Geometric mean ratios comparing pneumococcal conjugate vaccine-13 versus pneumococcal conjugate vaccine-10 favoured pneumococcal conjugate vaccine-13 for serotypes 4, 9V and 23F at 1 month after primary vaccination series, with 1.14- to 1.54-fold significantly higher immunoglobulin G responses with pneumococcal conjugate vaccine-13. Risk of seroinfection prior to the time of booster dose was lower for pneumococcal conjugate vaccine-13 for serotype 4, 6B, 9V, 18C and 23F than for pneumococcal conjugate vaccine-10. Significant heterogeneity and inconsistency were present for most serotypes and for both outcomes. Twofold higher antibody after primary vaccination was associated with a 54% decrease in risk of seroinfection (relative risk 0.46, 95% confidence interval 0.23 to 0.96). In modelled scenarios, pneumococcal conjugate vaccine-13 or pneumococcal conjugate vaccine-10 introduction in 2006 resulted in a reduction in cases that was less rapid for pneumococcal conjugate vaccine-10 than for pneumococcal conjugate vaccine-13. The pneumococcal conjugate vaccine-13 programme was predicted to avoid an additional 2808 (95% confidence interval 2690 to 2925) cases of invasive pneumococcal disease compared with pneumococcal conjugate vaccine-10 introduction between 2006 and 2030. Limitations Analyses used data from infant vaccine studies with blood samples taken prior to a booster dose. The impact of extrapolating pre-booster efficacy to post-booster time points is unknown. Network meta-analysis models contained significant heterogeneity which may lead to bias. Conclusions Serotype-specific differences were found in immunogenicity and seroefficacy between pneumococcal conjugate vaccine-13 and pneumococcal conjugate vaccine-10. Higher antibody response after vaccination was associated with a lower risk of subsequent infection. These methods can be used to compare the pneumococcal conjugate vaccines and optimise vaccination strategies. For future work, seroefficacy estimates can be determined for other pneumococcal vaccines, which could contribute to licensing or policy decisions for new pneumococcal vaccines. Study registration This study is registered as PROSPERO CRD42019124580. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/148/03) and is published in full in Health Technology Assessment; Vol. 28, No. 34. See the NIHR Funding and Awards website for further award information. Plain language summary Pneumococcal disease is a serious illness caused by a bacterial infection that can result in death. Children in the United Kingdom receive a vaccine to prevent this disease that protects against 13 different types of pneumococcal diseases. It is very effective, but other vaccines are also available, such as one that contains 10 types of pneumococcal diseases. Vaccines in the United Kingdom are bought by the government and the choice of which vaccine to provide is based on the cost of the vaccine as well as the benefits to our health. However, there is very little information comparing different vaccines and it is often assumed they are the same. We did a large analysis combining all studies of the two main licensed pneumococcal vaccines to determine which vaccine provides better protection against infection and how this affects costs. We used information from studies published in medical journals, and also data from studies done by the companies that own the vaccines. Our results showed that pneumococcal conjugate vaccine-13 vaccine provided better protection than pneumococcal conjugate vaccine-10 for 5 of the 10 serotypes that are contained in both vaccines. When we used these results to model what might have happened had either of these vaccines been introduced into the United Kingdom vaccination programme in 2006, we found that both vaccines caused a rapid decrease in the amount of disease, but that the decrease in disease was faster with pneumococcal conjugate vaccine-13 than pneumococcal conjugate vaccine-10. This resulted in 2808 cases of diseases prevented over a 25-year time frame with pneumococcal conjugate vaccine-13 compared with pneumococcal conjugate vaccine-10. Our methods can be used to compare other vaccines and we recommend this type of study be done in future when making decisions on vaccine product choice. Scientific summary Streptococcus pneumoniae (pneumococcus) causes severe diseases, including bacterial pneumonia, meningitis and sepsis, leading to substantial morbidity and mortality worldwide, with the highest disease burden being in young children and older adults. Three pneumococcal conjugate vaccines (PCVs) have been widely deployed worldwide in the past two decades: PCV7 (Prevnar; Pfizer, headquartered in New York City, New York, USA), PCV10 (Synflorix; GlaxoSmithKline, headquartered in Brentford, London, UK) and PCV13 (Prevenar 13; Pfizer, headquartered in New York City, New York, USA), resulting in substantial reduction in disease. Between 2009 and 2011, PCV7 was gradually replaced by PCV13 and PCV10 and is no longer available. The World Health Organization (WHO) does not preferentially endorse one PCV over another. Both PCV13 and PCV10 have been shown to provide both direct and indirect protection against pneumococcal pneumonia, invasive pneumococcal disease and nasopharyngeal carriage. Although there are 10 common serotypes in these 2 vaccines, the components of the vaccines differ, with different carrier proteins used in the conjugation process, as well as different amounts of polysaccharide, and these differences may contribute to differences in protection. Large randomised controlled trials directly comparing different PCVs with invasive pneumococcal disease as the primary outcome are not feasible. We previously used ‘seroinfection’ as an outcome for analysis of PCVs, where seroinfection is defined as an increase in antibody levels between the primary vaccination series (typically complete at 5–7 months of age) and the booster dose (typically administered at 9–18 months of age). Seroinfection can be regarded as evidence of exposure to the pathogen and a resultant subclinical infection, given antibody responses wane rapidly during this period otherwise. Seroinfection rates for different vaccines can be compared by calculating the relative risk (RR) of seroinfection, referred to herein as ‘seroefficacy’. We meta-analysed data from studies of PCVs to compare the immunogenicity and seroefficacy of PCV10 with PCV13 for each serotype. We aimed to determine if serotype-specific immune responses were higher for either vaccine and whether this resulted in greater protection again seroinfection. In addition, we explored the overall relationship between the higher immune response and protection against seroinfection in infants. Following this, we show how serotype-specific estimates of seroefficacy can be incorporated in vaccine cost-effectiveness models. Objectives The primary objective of the systematic review was to compare the immunogenicity of PCV10 versus PCV13 for each serotype contained in the vaccines. The secondary objectives were: to compare the seroefficacy of PCV10 versus PCV13 for each serotype contained in the vaccines for PCV10 and PCV13 separately, to estimate immunogenicity and seroefficacy in comparison with the older PCV7 vaccine to determine how the comparisons of immunogenicity and efficacy of PCV10 to PCV13 are affected by the co-administration of different routine vaccines. Methods Systematic review We conducted a systematic review identifying studies that compared the immunogenicity of licensed PCVs in trials which randomised children to one of two different PCVs. The PCVs included in the review were PCV7 (Prevnar; Pfizer), PCV10 (Synflorix; GlaxoSmithKline) and PCV13 (Prevenar 13; Pfizer); PCV7 was included even though no longer available, so that we could compare PCV13 and PCV10 indirectly through them each being compared with PCV7 for the same serotypes. Data sources The databases searched were Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials, EMBASE, Global Health and MEDLINE. The trial registers searched were ClinicalTrials.gov (https://clinicaltrials.gov/) and WHO International Clinical Trials Registry Platform (https://trialsearch.who.int/). The search comprised title/abstract keywords and subject headings for pneumococcal vaccines and children. A methodological search filter for randomised controlled trials taken from the Cochrane Handbook was used to limit to randomised controlled trials. Pharmaceutical company websites (GlaxoSmithKline and Pfizer) were also hand-searched for relevant studies. No date or language limits were applied. Study selection Randomised controlled trials were included if they provided direct comparisons of either PCV7, PCV10 or PCV13 among infants and children ˂ 2 years of age, and if they provided estimates of antibody responses [serotype-specific anti-pneumococcal immunoglobulin G (IgG) to PCVs for at least one time point of 1] between 4 and 6 weeks after the primary vaccination series and/or 1 month after a booster vaccination. Individual participant-level data were retrieved if available. Aggregate data from publications were extracted if individual participant data were not available. Risk of bias in results of the included studies was assessed independently by two reviewers using the Cochrane Risk of Bias Tool. Data synthesis Each trial with individual participant-level data available was analysed to obtain the log of the ratio of geometric means (log-GMR) and its standard error (SE) for each serotype and time point of interest. The RR of seroinfection was estimated by comparing the proportion of participants with seroinfection between vaccine groups. When no seroinfection occurred in any group (numerator of absolute risk was 0), a small non-zero value (0.5) was added to both sero-infected and sero-non-infected groups to allow estimation of the RR. The log-GMRs, log-RRs and their SEs constituted the input data for evidence synthesis. Only trials supplying individual participant data were included in seroefficacy analyses. For serotypes contained in all three vaccines, evidence could be synthesised using a network meta-analysis (NMA) of all comparisons. For other serotypes, meta-analysis was used for evidence synthesis. To estimate the overall association between antibody geometric mean ratio (GMR) and RR across all serotypes, we fitted a mixed-effect model regressing study-level RRs of seroinfection on GMRs across serotypes, weighted by the sample size of each study. Fixed effects included GMR, serotype and interactions between GMR and serotype (allowing serotype-specific association), while study was included as a random effect. Mathematical modelling and retrospective economic evaluation To illustrate the use of serotype-specific estimates of seroefficacy in modelling vaccine impact and cost-effectiveness, we developed a serotype-specific mathematical model of pneumococcal transmission dynamics to compare the differential impact of PCV10 and PCV13 introduction on invasive pneumococcal disease cases with vaccine serotypes in England and Wales. The model estimated the impact over a 25-year time period from 2006 to 2030. We subsequently assessed the cost-effectiveness of introducing infant vaccination with PCV13 compared with introducing PCV10 from a healthcare payer perspective in England and Wales. More specifically, we retrospectively estimated the additional threshold price per dose below which PCV13 would be more cost-effective than PCV10 had they both been available at the time of introduction of the PCV vaccine programme in England and Wales in 2006. Results Database registry and hand searches identified 4699 publication records of which 47 studies (78 publication reports) satisfied our eligibility criteria. Nineteen studies (24 publication reports) were excluded from the analysis: 6 studies did not provide individual patient or aggregate data and 13 studies (18 publication reports) were studies with the vaccines of interest, but it was not possible to form a loop within the NMA to provide indirect evidence. The remaining 28 studies (54 publication records) from 2009 to 2023 were included in the NMAs. Twenty-two studies provided individual participant data with a further five studies reporting aggregate data. Immunogenicity Geometric mean ratios for comparisons between PCV13 versus PCV10 for any primary series schedule were higher for PCV13 for serotypes 4, 7F, 9V and 23F at 1 month after primary vaccination series, with 1.14- to 1.54-fold higher IgG responses with PCV13. Additional serotypes contained only in the PCV13 vaccine (3, 6A and 19A) also favoured PCV13 as expected. GMRs were similar for the remaining serotypes (1, 5, 6B, 14, 18C and 19F). GMRs favoured PCV7 over either PCV13 or PCV10 for serotypes 4, 6B, 9V, 14 and 23F. There was no difference in GMRs for serotypes 18C and 19F across three vaccines. At the pre-booster time point, data were available from 18 cohorts. IgG responses were lower with PCV13 compared with PCV10 for all PCV7 serotypes except for serotype 14, with the point estimates of GMRs comparing PCV13 versus PCV10 ranging from 0.44 to 0.78. IgG responses were higher for PCV13 for serotypes 1, 5 and 7F. GMRs comparing PCV13 versus PCV7 showed higher IgG with PCV7 for serotypes 4, 6B, 9V, 14 and 23F and higher IgG with PCV13 for serotype 19F. At 28 days post booster, data were available from 26 cohorts. GMRs favoured PCV13 over PCV10 for serotype 6B, 9V, 14 and 23F and favoured PCV10 over PCV13 for serotype 18C. For serotype 1, 5 and 7F, antibody responses were higher in PCV13 compared with PCV10. PCV7 recipients had higher geometric mean concentrations (GMCs) compared with PCV13 for all PCV7 serotypes except 6B for which there was no difference, and 19F, which favoured PCV13. For PCV13-only serotypes (3, 6A and 19A), GMRs favour PCV13 at all three time points. Substantial heterogeneity and network inconsistency were present for most serotypes at all three time points. To explore potential reasons for the observed heterogeneity, we summarised cohort-level GMRs and RRs for each vaccine comparison. These descriptive analyses revealed a lack of consistency in the direction of study-level estimates within each vaccine comparison, resulting in the significant heterogenicity. There was also no observable pattern in any trial-level variable (region, co-administered vaccines, vaccine schedule), from which one might propose a mechanism that would adequately explain this variation in GMRs. Seroefficacy There were 12 studies (15 cohorts) with available individual participant antibody data at both post-primary and prior to the booster dose, allowing serotype-specific estimation of seroefficacy from a total of 5152 participants. Of these 15 cohorts, 6 compared PCV10 versus PCV7, 3 compared PCV13 versus PCV7 and 6 compared PCV13 versus PCV10. Among PCV7 serotypes, the risk of seroinfection was lower with PCV13 than PCV10 for serotypes 4, 6B, 9V, 18C and 23F, while no difference was seen for serotype 14 and 19F. The RRs of seroinfection (PCV13 vs. PCV10) for PCV7 serotypes ranged from 0.32 (95% CI 0.19 to 0.52) for serotype 4 to 1.28 (95% CI 0.95 to 1.74) for serotype 14. For serotypes 1, 5 and 7F, evidence was summarised from six studies directly comparing PCV13 with PCV10. Comparisons between PCV13 and PCV7 favoured neither vaccine over the other, whereas comparisons between PCV7 and PCV10 favoured PCV7 for serotypes 5, 6B, 9V, 18C and 23F. The I2 and p-values indicated some heterogeneity for all PCV7 serotypes except for serotype 4 and 19F. In the mixed-effects model of all serotypes combined, vaccines that produced the same amount of antibody (GMR = 1) had very similar protection (adjusted RR 0.80, 95% CI 0.41 to 1.58). The model estimate indicates that for each twofold increase in antibody response, the risk of seroinfection was halved (GMR of 2.0; RR 0.46, 95% CI 0.23 to 0.96). Mathematical model and economic evaluation Mathematical model results showed that in the absence of any vaccine programme, an increase in invasive pneumococcal disease cases caused by all five serotypes would be seen over the 25-year time frame. With the introduction of either PCV13 or PCV10 vaccine programmes in 2006, case counts would have decreased, achieving near eradication of all serotypes within the time frame modelled. The decrease in cases was most rapid for serotype 6B and least rapid for serotype 4. The decrease in cases was less rapid for PCV10 than for PCV13 due to the lower seroefficacy. The introduction of an infant PCV13 programme was predicted to avoid an additional 2808 (95% CI 2690 to 2925) cases of invasive pneumococcal disease compared with PCV10 introduction between 2006 and 2030. This includes an estimated 326 cases of meningitis, 578 cases of sepsis, 1770 cases of invasive pneumonia and 30,680 cases of non-invasive pneumonia. Under base-case assumptions, this resulted in discounted healthcare savings of £13 million (95% CI £12 to £14 million). Including non-invasive pneumonia increased the savings to £27 million (95% CI £25 to £29 million). Conclusions In our study, we used a novel methodology to define seroinfection from immunogenicity data to compare the relative efficacy of PCVs in preventing infection. Our results using individual-level data from a global meta-analysis provide the first estimates of the comparative protection afforded by different pneumococcal vaccines and show that for many serotypes, carriage events are less common after PCV13 than PCV10, likely due to a higher antibody response. In addition, we quantify the relationship between the immune response to vaccination and protection against infection, measured serologically, and show that higher antibody responses in infants are associated with greater protection from infection. Licensure of new vaccines is based on non-inferiority comparisons with current vaccines and the proportion of antibody responses above the agreed threshold as a minimum requirement. Once a vaccine meets this ‘at-least-as-good-as’ immunogenicity criteria, it has previously not been clear whether exceeding it is of benefit, and the WHO position paper on pneumococcal vaccines states ‘It is unknown whether a lower serotype-specific GMC of antibody indicates less efficacy’. Our results show that lower protection against subclinical infection does indeed follow from lower antibody production and that two vaccines that produce a similar level of antibody will provide similar levels of protection. The implications of these findings are of greatest importance when a new vaccine roll-out is being considered. Lower antibody production or lower seroefficacy for one vaccine product does not necessarily imply limited effectiveness against invasive pneumococcal diseases when considering vaccines such as PCV10 and PCV13 which are highly effective vaccines in many settings. Instead, lower antibody responses lead to less rapidly observed indirect protection after implementation into a national programme as a smaller proportion of transmission events are blocked by the vaccine. This is evident in the mathematical modelling which showed less rapid decreases in the number of cases of invasive disease when introducing PCV10 compared with PCV13. Implications for practice This evidence of differences in serotype-specific protection can be incorporated into cost-effectiveness models used to compare vaccine products. Cost-effectiveness studies have highlighted the lack of evidence of comparative efficacy for different PCVs, resulting in previous cost-effectiveness models that ignore serotype-specific differences and assume equivalent efficacy for all serotypes covered by different PCVs. Our study fills this evidence gap and allows researchers and policy-makers to use more accurate vaccine-specific models in decision-making. Our cost-effectiveness analysis of a hypothetical scenario showed that introducing infant PCV13 was predicted to avert a higher burden of pneumococcal disease compared with PCV10. This would have realised a small saving of £13 million discounted over 24 years. When considering the introduction of new pneumococcal vaccines into the routine immunisation schedule, we recommend that differences in antibody responses for different vaccines be considered in modelling scenarios as higher antibody responses result in reduced transmission and greater impact on invasive diseases. Vaccine-specific threshold prices can then be determined for cost-effective vaccines. Our analysis showed that due to its higher efficacy against some serotypes, a higher threshold price per dose could be paid for PCV13 while remaining cost-effective. Study registration This study is registered as PROSPERO CRD42019124580. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/148/03) and is published in full in Health Technology Assessment; Vol. 28, No. 34. See the NIHR Funding and Awards website for further award information.
- Published
- 2024
- Full Text
- View/download PDF
26. Characterization of Streptococcus pneumoniae isolates obtained from the middle ear fluid of US children, 2011–2021
- Author
-
Lindsay R. Grant, Kevin Apodaca, Lalitagauri Deshpande, John H. Kimbrough, Kyla Hayford, Qi Yan, Rodrigo Mendes, Alejandro Cané, Bradford D. Gessner, and Adriano Arguedas
- Subjects
otitis media ,Streptococcus pneumoniae ,pneumococcal conjugate vaccine ,serotype distribution ,antimicrobial susceptibility ,Pediatrics ,RJ1-570 - Abstract
IntroductionPneumococcal conjugate vaccines (PCVs), including higher valency vaccines such as PCV20, have the potential to reduce pediatric otitis media. We assessed serotype distribution, potential PCV coverage, and antimicrobial susceptibility of Streptococcus pneumoniae isolates cultured from middle ear fluid (MEF) of US children age ≤5 years.MethodsS. pneumoniae isolates identified from US hospitals participating in the SENTRY Antimicrobial Surveillance program from 2011 to 2021 were included. Serotypes were determined by in silico analysis based on Pneumococcal Capsular Typing methodology. The percentage of isolates belonging to serotypes included in PCV13 (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), PCV15 (PCV13 plus 22F, 33F), and PCV20 (PCV13 plus, 8, 10A, 11A, 12F, 15B, 22F and 33F) was calculated. Antimicrobial susceptibility testing was performed by broth microdilution and interpreted using CLSI criteria. Nonsusceptibility was defined as isolates that were intermediate or resistant to a selected antimicrobial.ResultsAmong the 199 S. pneumoniae isolates that were identified, 56.8% were from children age
- Published
- 2024
- Full Text
- View/download PDF
27. Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study
- Author
-
Lewnard, Joseph A, Bruxvoort, Katia J, Hong, Vennis X, Grant, Lindsay R, Jódar, Luis, Cané, Alejandro, Gessner, Bradford D, and Tartof, Sara Y
- Subjects
Lung ,Vaccine Related ,Pneumonia ,Immunization ,Pneumonia & Influenza ,Prevention ,Infectious Diseases ,Clinical Research ,Infection ,Humans ,Adult ,Case-Control Studies ,Respiratory Tract Infections ,Streptococcus pneumoniae ,Viruses ,Vaccination ,Vaccines ,Conjugate ,Pneumococcal Vaccines ,Respiratory Syncytial Virus ,Human ,Pneumococcal Infections ,Pneumonia ,Pneumococcal ,pneumococcal conjugate vaccine ,influenza ,respiratory syncytial virus ,parainfluenza virus ,human metapneumovirus ,pneumonia ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundInteractions of Streptococcus pneumoniae with viruses feature in the pathogenesis of numerous respiratory illnesses.MethodsWe undertook a case-control study among adults at Kaiser Permanente Southern California between 2015 and 2019. Case patients had diagnoses of lower respiratory tract infection (LRTI; including pneumonia or nonpneumonia LRTI diagnoses), with viral infections detected by multiplex polymerase chain reaction testing. Controls without LRTI diagnoses were matched to case patients by demographic and clinical attributes. We measured vaccine effectiveness (VE) for 13-valent (PCV13) against virus-associated LRTI by determining the adjusted odds ratio for PCV13 receipt, comparing case patients and controls.ResultsPrimary analyses included 13 856 case patients with virus-associated LRTI and 227 887 matched controls. Receipt of PCV13 was associated with a VE of 24.9% (95% confidence interval, 18.4%-30.9%) against virus-associated pneumonia and 21.5% (10.9%-30.9%) against other (nonpneumonia) virus-associated LRTIs. We estimated VEs of 26.8% (95% confidence interval, 19.9%-33.1%) and 18.6% (9.3%-27.0%) against all virus-associated LRTI episodes diagnosed in inpatient and outpatient settings, respectively. We identified statistically significant protection against LRTI episodes associated with influenza A and B viruses, endemic human coronaviruses, parainfluenza viruses, human metapneumovirus, and enteroviruses but not respiratory syncytial virus or adenoviruses.ConclusionsAmong adults, PCV13 conferred moderate protection against virus-associated LRTI. The impacts of pneumococcal conjugate vaccines may be mediated, in part, by effects on polymicrobial interactions between pneumococci and respiratory viruses.
- Published
- 2023
28. Molecular characteristics and antimicrobial resistance of invasive pneumococcal isolates from children in the post-13-valent pneumococcal conjugate vaccine era in Shenzhen, China
- Author
-
Lu Huang, Yanmin Bao, Qiuwei Yi, Dingle Yu, Heping Wang, Hongmei Wang, Zihao Liu, Chunqing Zhu, Qing Meng, Yunsheng Chen, Wenjian Wang, Jikui Deng, Gang Liu, Yuejie Zheng, and Yonghong Yang
- Subjects
Streptococcus pneumoniae ,Invasive pneumococcal disease ,Serotypes ,Antibiotic resistance ,Pneumococcal conjugate vaccine ,Children ,Microbiology ,QR1-502 - Abstract
ABSTRACT: Objectives: This study aimed to evaluate the molecular epidemiology and antimicrobial resistance of invasive pneumococcal isolates from children in Shenzhen, China, in the early stage of the pneumococcal 13-valent conjugated vaccine (PCV-13) era from 2018 to 2020. Methods: Invasive pneumococcal strains were isolated from hospitalized children with invasive pneumococcal diseases (IPDs) from January 2018 to December 2020. The serotype identification, multilocus sequence typing (MLST), and antibiotic susceptibility tests were performed on all culture-confirmed strains. Results: Sixty-four invasive strains were isolated mainly from blood (70.3%). Prevalent serotypes were 23F (28.1%), 14 (18.8%), 19F (15.6%), 6A/B (14.1%), and 19A (12.5%), with a serotype coverage rate of 96.9% for PCV13. The most common sequence types (STs) were ST876 (17.1%), ST271 (10.9%), and ST320 (7.8%). Half of the strains were grouped in clonal complexes (CCs): CC271 (21.9%), CC876 (20.3%), and CC90 (14.1%). Meningitis isolates showed a higher resistance rate (90.9% and 45.5%) to penicillin and ceftriaxone than the rate (3.8% and 9.4%) of non-meningitis isolates. The resistance rates for penicillin (oral), cefuroxime, and erythromycin were 53.13%, 73.4%, and 96.9%, respectively. The dual ermB and mefA genotype was found in 81.3% of erythromycin-resistant strains. The elevated minimum inhibitory concentration (MIC) of β-lactam antibiotics and dual-genotype macrolide resistance were related mainly to three major serotype-CC combinations: 19F-CC271, 19A-CC271, and 14-CC876. Conclusion: Invasive pneumococcus with elevated MICs of β-lactams and increased dual ermB and mefA genotype macrolide resistance were alarming. Expanded PCV13 vaccination is expected to reduce the burden of paediatric IPD and to combat antibiotic-resistant pneumococcus in Shenzhen.
- Published
- 2024
- Full Text
- View/download PDF
29. Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021
- Author
-
Claire von Mollendorf, Munkhchuluun Ulziibayar, Cattram D. Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, John de Campo, Margaret de Campo, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Eileen M. Dunne, Catherine Satzke, Tuya Mungun, and E. Kim Mulholland
- Subjects
pneumonia ,pneumococcal conjugate vaccine ,PCV13 ,hospitalization ,children ,bacteria ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine’s effect on pneumonia incidence rates among children 2–59 months of age over a 6-year period. Of 17,607 children with pneumonia, overall adjusted incidence rate ratios showed decreased primary endpoint pneumonia, very severe pneumonia, and probable pneumococcal pneumonia until June 2021. Results excluding and including the COVID-19 pandemic period were similar. Pneumonia declined in 3 districts that introduced PCV13 with catch-up campaigns but not in the 1 district that did not. After PCV13 introduction, vaccine-type pneumococcal carriage prevalence decreased by 44% and nonvaccine-type carriage increased by 49%. After PCV13 introduction in Mongolia, the incidence of more specific pneumonia endpoints declined in children 2–59 months of age; additional benefits were conferred by catch-up campaigns.
- Published
- 2024
- Full Text
- View/download PDF
30. Strategies for pneumococcal vaccination in older adults in the coming era
- Author
-
Kei Nakashima and Wakaba Fukushima
- Subjects
Pneumococcal conjugate vaccine ,pneumococcal polysaccharide vaccine ,invasive pneumococcal disease ,pneumococcal pneumonia ,older adults ,Immunologic diseases. Allergy ,RC581-607 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
ABSTRACTPneumonia, predominantly caused by Streptococcus pneumoniae, remains a leading cause of global mortality. The 23-valent Pneumococcal polysaccharide vaccine (PPSV23) and conjugate vaccines (PCVs) are vital measures to fight against it. This paper discussed the changes in pneumococcal vaccination strategies, particularly for older adults, as vaccine effectiveness and epidemiological patterns shift. While PPSV23 maintains effectiveness against invasive pneumococcal disease (IPD), its effectiveness against pneumococcal pneumonia is declining. Conversely, PCV13 consistently demonstrates effectiveness against both IPD and pneumonia. Consequently, the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices recommends using PCVs, notably PCV20 and PCV15, over PPSV23. Japanese studies indicate a change in the efficacy/effectiveness of PPSV23 following PCV introduction in children, likely owing to serotype replacement and herd immunity. Additionally, recent data reveals a plateau in the reduction of PCV13 and PPSV23-covered serotypes, posing a challenge to current strategies. This paper indicates a paradigm shift in pneumonia management, acknowledging its chronic nature and potential to exacerbate other diseases. The future of pneumococcal vaccination lies in broader serotype coverage through PCVs, adapting to serotype changes driven by childhood vaccination programs. Furthermore, continuous research and vaccine development are crucial in this evolving field.
- Published
- 2024
- Full Text
- View/download PDF
31. A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)
- Author
-
Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi “Lucy” Li, Yae-Jean Kim, Yun-Kyung Kim, Jin Lee, Ji Young Park, Dong Hyun Kim, GyongSeon Yang, Hyunjung Lim, Jin Oh Kim, Robert Lupinacci, Tina M. Sterling, Marissa Wilck, Alejandra Esteves-Jaramillo, and Natalie Banniettis
- Subjects
Vaxneuvance™ ,PCV15 ,pneumococcal conjugate vaccine ,infants ,toddlers ,Immunologic diseases. Allergy ,RC581-607 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
ABSTRACTThere is an ongoing burden of pneumococcal disease in children despite the use of pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite, descriptive study was designed to evaluate the safety and immunogenicity of a 3 + 1 regimen of V114 (VAXNEUVANCE™), a 15-valent PCV, in South Korean infants and toddlers. Adverse events (AEs) were reported for 14 d following any vaccination, and throughout the study period for serious AEs. Serotype-specific immunoglobulin G (IgG) response rates (proportion of participants meeting an IgG threshold value of ≥0.35 μg/mL) and geometric mean concentrations (GMCs) for the 15 serotypes at 30 d postdose 3 (PD3) and at 30 d postdose 4 (PD4) were evaluated as endpoints. Healthy infants enrolled at 42–90 d after birth were vaccinated with V114 (N = 57). The most commonly reported AEs were those solicited in the trial. The majority of reported AEs were transient and of mild or moderate intensity. Few serious AEs were reported; none were vaccine related. No participants died nor discontinued the study vaccine because of an AE. V114 was immunogenic for all 15 serotypes contained in the vaccine, as assessed by IgG response rates at 30 d PD3 and IgG GMCs at 30 d PD3 and at 30 d PD4. V114 was well tolerated and immunogenic when administered as a 3 + 1 regimen in healthy South Korean infants and toddlers.
- Published
- 2024
- Full Text
- View/download PDF
32. Introduction of the pneumococcal conjugate vaccine in humanitarian and fragile contexts: Perspectives from stakeholders in four African countries
- Author
-
Baldeep K. Dhaliwal, Rose Weeks, Jasmine Huber, Aminata Fofana, Mohamed Bobe, Antoinette Demian Mbailamen, George Legge, Gassim Cisse, and Anita Shet
- Subjects
Pneumonia ,pneumococcal conjugate vaccine ,fragile contexts ,health policy ,decision-making ,Immunologic diseases. Allergy ,RC581-607 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
ABSTRACTChildhood pneumonia causes a significant burden of preventable child morbidity and mortality in Chad, Guinea, Somalia/Somaliland, and South Sudan. Leaders from these countries have committed to reducing this burden and are preparing to introduce the pneumococcal conjugate vaccine (PCV) into their immunization programs. To support long-term sustainability for expected PCV introductions in settings afflicted by prolonged humanitarian crises this research explores national stakeholders’ perspectives on contextual factors that may influence optimal vaccine implementation. This qualitative study used purposive sampling to identify and interview stakeholders involved in vaccine decision-making. Interview transcripts were analyzed through the framework method, an approach involving charting data into pre-populated matrices. Findings from interviews with 16 key informants from government, partner organizations, and international health agencies fit within the following four overarching themes: (1) population-level vulnerabilities to pneumonia, exacerbated by climatic risks and low levels of maternal education; (2) disease burden and the interest in enhancing surveillance to monitor vaccine impact and integrate disease control efforts; (3) policy processes, including formalizing vaccine decision-making; and (4) vaccine implementation preparation, including the conduct of robust communication campaigns, training, and cold chain upgrades. This research explores perspectives from leaders in these countries which are at pivotal moments in their journeys toward introducing PCV. Widespread commitment among leaders, in addition to financial support, will facilitate vaccine introduction. Further, fostering a shared understanding among partners about context-specific determinants of program success will help build tailored implementation strategies for each country.
- Published
- 2024
- Full Text
- View/download PDF
33. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
- Author
-
Kang, Dong-Won, Kim, Chae-Rin, Song, Joon Young, and Park, Sun-Kyeong
- Subjects
- *
OLDER people , *PNEUMOCOCCAL vaccines , *COST effectiveness , *GLYCOCONJUGATES , *POLYSACCHARIDES - Abstract
Despite the demonstrated immunogenicity and safety of the 20-valent pneumococcal conjugate vaccine (PCV20) in older adults, the cost-effectiveness of the PCV20 was not examined compared to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in South Korea. Therefore, this study aimed to evaluate the cost-effectiveness of PCV20 compared with PPSV23 in adults aged 65 years and older in South Korea. We constructed a Markov model that included susceptible states, invasive pneumococcal disease (IPD), non-bacteremic pneumonia (NBP), and death. The population was categorized by disease risk status (low risk, moderate risk, and high risk) and age group (65–74/75–84/85–99 years) at model entry. The annual incidence and mortality of IPD and NBP associated with PCV20 and PPSV23 were estimated based on serotype coverage, vaccine coverage, and vaccine effectiveness. The disease costs and utilities were obtained from previous studies. The incremental cost-effectiveness ratio (ICER) was used to evaluate cost-effectiveness within the threshold of 16,824 USD per quality-adjusted life-year (QALY). Among the total population (n = 8,843,072), PCV20 prevented 1941 and 50,575 cases of IPDs and NBPs, respectively, and 898 and 8593 deaths due to IPDs and NBPs compared to PPSV23. The total medical cost per person was 12.11 USD higher in PCV20, with a gain of 0.0053 LYs and 0.0045 QALYs per person. The ICER for PCV20 and PPSV23 was 2270 USD/LY and 2677 USD/QALY. In South Korea, PCV20 is a cost-effective option compared with PPSV23 for adults aged 65 years and older. These cost-effectiveness results provide evidence for decision-making regarding the approval and National Immunization Program implementation of PCV20. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data.
- Author
-
Kim, Ju Hwan, Yoon, Dongwon, Lee, Hyesung, Choe, Young June, and Shin, Ju-Young
- Subjects
- *
PNEUMOCOCCAL vaccines , *VACCINATION of children , *FEBRILE seizures , *IMMUNIZATION , *POISSON regression - Abstract
Background Despite the general consensus on the safety of pneumococcal conjugate vaccine (PCV), safety concerns unveiled during post-licensure surveillance need to be addressed. We investigated whether there is a transient increased risk following a three-dose series of pneumococcal conjugate vaccine (PCV) administered at 2, 4 and 6 months of age. Methods This was a population-based cohort study using the Korea immunization registry data linked to nationwide administrative claims data. Self-controlled risk interval analysis was conducted for PCV recipients who had an outcome of interest within pre-defined risk and control intervals between 2018 and 2022. The outcomes were anaphylaxis, asthma, encephalopathy, febrile seizure, Kawasaki disease and thrombocytopenia. We used conditional Poisson regression model to estimate the incidence rate ratios (IRRs) and 95% confidence intervals (CIs) comparing the outcomes in the risk and control intervals. Results Of 1 114 096 PCV recipients, 8661 had outcomes either in the risk or control intervals. Their mean age at Dose 1 was 10.0 weeks, 58.3% were boys, and 85.3% received 13-valent PCV. PCV was not associated with an increased risk of any outcomes except for febrile seizure. There were 408 (56.0%) cases of febrile seizure in the risk interval, corresponding to an IRR of 1.27 (95% CI 1.10–1.47). Conclusions It is reassuring to note that there was no increased risk of the potential safety concerns following PCV administration. Despite the transient increased risk of febrile seizure, absolute numbers of cases were small. Febrile seizure is generally self-limiting with a good prognosis, and should not discourage parents or caregivers from vaccinating their children. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland.
- Author
-
Alexandrova Nikolova, Kristiana, Andersson, Mikael, Slotved, Hans-Christian, and Koch, Anders
- Subjects
PNEUMOCOCCAL vaccines ,VACCINATION of children ,DEATH rate ,AGE groups ,MORTALITY ,HAEMOPHILUS diseases - Abstract
Before the incorporation of the 13-valent pneumococcal conjugate vaccine (PCV13) into the childhood vaccination regimen in Greenland in 2010, Inuit populations experienced a substantial prevalence of invasive pneumococcal disease (IPD). The PCV13 introduction has been shown to markedly reduce the incidence of IPD. This current study estimated the impact of PCV13 introduction on IPD mortality in Greenland. This was a nationwide register-based study using all available data on IPD cases 1995–2020 in Greenland. Thirty-one-day IPD case fatality rates (CFR), and all-cause and mortality rates associated with IPD during the period before the introduction of PCV13 (January 1995 to September 2010) were compared with those observed in the post-PCV13 era (September 2010 to October 2020). Standardized mortality ratios (SMRs) expressed differences in mortality by sex, age, region, ethnicity, comorbidity, and serotype. IPD CFR decreased with 24.5% from the pre- to the post-PCV13 period. SMR in IPD patients decreased by 57% (95% CI, 36–75%), and a reduction occurred in all age groups. While SMR in IPD persons ≥60 years remained virtually unchanged, there were no IPD-related deaths in persons ≤39 years in the post-PCV13 period. In conclusion, IPD-related mortality has decreased in Greenland following PCV13 introduction in 2010 in the country. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines.
- Author
-
Grozdanovic, Milica, Samuel, Rachelle, Grau, Brendan, and Ansbro, Frances
- Abstract
The Streptococcus pneumoniae bacteria has over 100 known serotypes that display a continuous change in prevalence by patients' age and geographical location and therefore necessitate continued efforts toward development of new vaccines with broader protection. Glycoconjugate vaccines have been instrumental in reducing global morbidity and mortality caused by Streptococcus pneumoniae infections. In these vaccines, the bacterial polysaccharide is conjugated to a carrier protein to enhance immunogenicity. To ensure well defined immunogenicity and stability of conjugated vaccines, reliable quantification of non-conjugated (free) polysaccharide is a critical, albeit challenging step during vaccine clinical dosing, release and stability monitoring. Multivalent preparations of Cross-reactive material 197 (CRM197)- conjugated pneumococcal polysaccharide materials often contain only nanogram levels of each individual free polysaccharide at final container concentrations. We have developed a novel method for the separation of free polysaccharides from conjugated material that requires no sample derivatization, employing instead an approach of quantitative immunoprecipitation of CRM197 with 3 different monoclonal antibodies and magnetic beads. A mix of antibodies against both linear and conformational epitopes enables successful removal of conjugates regardless of the protein folded state. The remaining free polysaccharide is subsequently measured in a serotype-specific ELISA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
- Author
-
Reis, Joice Neves, Azevedo, Jailton, de Oliveira, Aisla Mércia Lazaro, Menezes, Ana Paula de Oliveira, Pedrosa, Mayara, dos Santos, Milena Soares, Ribeiro, Laise Carvalho, Freitas, Humberto Fonseca de, Gouveia, Edilane Lins, Teles, Marcelo Bastos, Carvalho, Maria da Glória, Reis, Mitermayer Galvão, Nascimento-Carvalho, Cristiana, and Verani, Jennifer R.
- Abstract
In 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10) in the national infant immunization program. Limited data on the long-term impact of PCV10 are available from lower-middle-income settings. We examined invasive pneumococcal disease (IPD) in Salvador, Bahia, over 11 years. Prospective laboratory-based surveillance for IPD was carried out in 9 hospitals in the metropolitan region of Salvador from 2008 to 2018. IPD was defined as Streptococcus pneumoniae cultured from a normally sterile site. Serotype was determined by multiplex polymerase chain reaction and/or Quellung reaction. Incidence rates per 100,000 inhabitants were calculated for overall, vaccine-type, and non-vaccine-type IPD using census data as the denominator. Incidence rate ratios (IRRs) were calculated to compare rates during the early (2010–2012), intermediate (2013–2015), and late (2016–2018) post-PCV10 periods in comparison to the pre-PCV10 period (2008–2009). Pre-PCV10, overall IPD incidence among all ages was 2.48/100,000. After PCV10 introduction, incidence initially increased (early post-PCV10 IRR 3.80, 95% CI 1.18–1.99) and then declined to 0.38/100,000 late post-PCV10 (IRR 0.15; 95% CI 0.09–0.26). The greatest reductions in the late post-PCV10 period were observed in children aged ≤2 years, with no cases (IRR not calculated) and those ≥60 years (IRR 0.11, 95% CI 0.03–0.48). Late post-PCV10, significant reductions were observed for both PCV10 serotypes (IRR 0.02; 95% CI 0.0–0.15) and non-PCV10 serotypes (IRR 0.27; 95%CI 0.14–0.53). Non-PCV10 serotypes 15B, 12F, 3, 17F, and 19A became predominant late post-PCV10 without a significant increase in serotype-specific IPD incidence compared to pre-PCV10. Significant declines in IPD, including among adults not eligible for vaccination, suggest direct and indirect protection up to nine years after PCV10 introduction, without evidence of significant replacement disease. Continued surveillance is needed to monitor changes in non-vaccine serotypes and inform decisions about introducing higher valent PCVs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Non-protective immunity after standard pneumococcal vaccination series identified as a potential contributing risk factor for refractory otolaryngologic conditions in children.
- Author
-
Bonaventure, Caroline A. and Evans, Adele K.
- Subjects
- *
STREPTOCOCCAL disease prevention , *IMMUNOGLOBULIN analysis , *OTOLARYNGOLOGY diagnosis , *POLYSACCHARIDES , *IMMUNIZATION , *CHILDREN'S hospitals , *STREPTOCOCCAL diseases , *PNEUMOCOCCAL vaccines , *PEDIATRICS , *VOLUMETRIC analysis , *RETROSPECTIVE studies , *ACQUISITION of data , *TERTIARY care , *REINFECTION , *JUVENILE idiopathic arthritis , *BACTERIAL antigens , *OTITIS media with effusion , *ANTIBODY formation , *IMMUNOLOGICAL deficiency syndromes , *DISEASE relapse , *MEDICAL records , *MEDICAL referrals , *AGAMMAGLOBULINEMIA , *IMMUNITY , *ELECTRONIC health records , *OTOLARYNGOLOGY , *EVALUATION , *CHILDREN - Abstract
Objective: To examine the relationship between conferred immunity after standard pneumococcal series and refractory otolaryngologic infections in pediatric patients using post-vaccination antibody titers, and to identify contributory underlying conditions revealed when vaccination/re-vaccination fails to confer protective immunity. Study Design: IRB-reviewed and "exempt" retrospective case series with chart review using the Epic® Electronic Medical Record system from 2013 to 2021. Setting: Dedicated tertiary referral children's hospital. Methods: Pneumococcal antibody titer results were assessed for children ages 0 to 21 years and: (1) at least 1 of 7 otolaryngologic disease diagnoses and (2) having received the 4-dose schedule of pneumococcal conjugate vaccine (PCV 7 or 13). Results: A total of 241 subjects met inclusion criteria with 356 laboratory tests. Recurrent acute otitis media, chronic rhinitis, and chronic otitis media with effusion were the 3 most frequent diagnoses. At presentation, only 27.0% of subjects had titers conferring immunity from their prior vaccinations with PCV. About 85 subjects had been subsequently revaccinated with Pneumococcal Polysaccharide Vaccine (PPSV), and antibody responses conferring immunity reached 91.8%. Seven subjects never developed adequate responses; 5 of these had recurrent acute otitis media as the primary otolaryngologic diagnosis. Secondary "revealed" diagnoses included Juvenile Rheumatoid Arthritis (n = 1), unresolved specific antibody deficiency (n = 2), and Hypogammaglobulinemia (n = 1). Conclusion: In pediatric patients with recurrent infectious otolaryngologic disease refractory to traditional medical and surgical therapy, inadequate responses to pneumococcal vaccination may be revealed. This correlation represents a potential pathway for diagnosis and therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. PCV13, PCV15 or PCV20: Which vaccine is best for children in terms of immunogenicity?
- Author
-
De Wals, Philippe
- Subjects
IMMUNE response ,VACCINE immunogenicity ,PNEUMOCOCCAL vaccines ,VACCINES ,TODDLERS - Abstract
Background: The new 15 and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) have been marketed on the basis of immunogenicity criteria, one of them being a non-inferior response as compared with the 13-valent vaccine (PCV13). In the past, PCV13 was also authorized on the basis of the same criteria, using the 7-valent vaccine (PCV7) as a reference. Methods: Our aim was to compare the immunogenicity of these three vaccines in toddlers. Functional opsonophagocytotic activity (OPA) titre ratios measured in the same and different randomized trials were computed to assess the respective immunogenicity of these four products. Results: Results suggest that both PCV15 and PCV20 are less immunogenic than PCV13 for most common serotypes and that the two new vaccines induce a broadly similar response. The PCV7 vaccine was already slightly more immunogenic than PCV13 meaning that PCV15 and PCV20 compare poorly with PCV7. Results also point towards a reduced immunogenicity of the 2+1 dose schedule compared to the 3+1 dose schedule for PCV13, PCV15 and PCV20. Conclusion: Post-marketing studies will have to be conducted to assess the effectiveness of PCV15 and PCV20 and their real-life benefit over PCV13. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Antimicrobial Resistance in Streptococcus pneumoniae before and after the Introduction of Pneumococcal Conjugate Vaccines in Brazil: A Systematic Review.
- Author
-
Knupp-Pereira, Patricia Alice, Cabral, Amanda Seabra, Dolores, Ítalo Moraes, da Silva, Amanda Beiral, Póvoa, Helvécio Cardoso Correa, and Neves, Felipe Piedade Gonçalves
- Subjects
STREPTOCOCCUS pneumoniae ,PNEUMOCOCCAL vaccines ,DRUG resistance in microorganisms ,NATIONAL territory ,POLYPOIDAL choroidal vasculopathy ,IMMUNOCOMPROMISED patients - Abstract
Streptococcus pneumoniae causes serious illnesses, such as pneumonia, bacteremia, and meningitis, mainly in immunocompromised individuals and those of extreme ages. Currently, pneumococcal conjugate vaccines (PCVs) are the best allies against pneumococcal diseases. In Brazil, the 10-valent and 13-valent PCVs have been available since 2010, but the threat of antimicrobial resistance persists and has been changing over time. We conducted a systematic review of the literature with works published since 2000, generating a parallel between susceptibility data on isolates recovered from colonization and invasive diseases before and after the implementation of PCVs for routine childhood use in Brazil. This systematic review was based on the Cochrane Handbook for Systematic Reviews of Interventions and Preferred Reporting Items for Systematic Literature Reviews and Meta-Analyses (PRISMA) guidelines. Despite the inclusion of PCVs at a large scale in the national territory, high frequencies of non-susceptibility to important drugs used in pneumococcal diseases are still observed, especially penicillin, as well as increasing resistance to macrolides. However, there are still drugs for which pneumococci have a comprehensive sensitivity profile. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Whole genome sequencing data of Streptococcus pneumoniae isolated from Indonesian population
- Author
-
Miftahuddin Majid Khoeri, Yustinus Maladan, Korrie Salsabila, Lindawati Alimsardjono, Naritha Vermasari, Iva Puspitasari, Rina Yunita, Wisnu Tafroji, Rosantia Sarassari, Ratna Fathma Sari, Sarah Azhari Balqis, Ghina Athyah Wahid, Diana Shinta Purwanto, Kuntjoro Harimurti, Amin Soebandrio, and Dodi Safari
- Subjects
Streptococcus pneumoniae ,Whole-genome sequence ,Pneumococcal conjugate vaccine ,Hospitalized patient ,Healthy children ,Adult ,Computer applications to medicine. Medical informatics ,R858-859.7 ,Science (General) ,Q1-390 - Abstract
Streptococcus pneumoniae is the leading cause of bacterial pneumonia, bacteremia, and meningitis. Indonesia introduced the pneumococcal conjugate vaccine (PCV) nationwide in 2022. In this study, we present whole genome sequence (WGS) data of 94 S. pneumoniae isolates that were obtained from hospitalized patients, healthy children, and adult groups from different regions prior to PCV program in Indonesia. DNA sequences of S. pneumoniae were obtained using the TruSeq Nano DNA kit (Illumina NovaSeq6000 Platform). The genome data of S. pneumoniae features a 1,969,562 bp to 2,741,371 bp circular chromosome with 39–40% G+Ccontent. The genome includes 1935–3319 coding sequences (CDS), 2 to 5 rRNA genes, 43 to 49 tRNA genes, and 56 to 71 ncRNA. These data will be useful for analyzing the serotype, sequence type, virulence genes, antimicrobial resistance genes, and the impact of pneumococcal vaccination in Indonesia. The FASTQ raw files of these sequences are available under BioProject accession number PRJNA995903 and Sequence Read Archive accession numbers SRR25316461-SRR25316554.
- Published
- 2024
- Full Text
- View/download PDF
42. 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study
- Author
-
Jiachen Wang, Yujue Wang, Ruoyu Xu, Ting Zhang, Yanyan Jiang, Yuanyuan Wang, Yi Wang, Yuanze Du, Wenxue Sun, Kai Deng, Weizhong Yang, Zengwu Wang, Luzhao Feng, and Chunping Wang
- Subjects
Pneumococcal conjugate vaccine ,Pneumococcal disease ,Non-immunization program ,Vaccination ,Vaccine-preventable disease ,Vaccination strategy ,Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal conjugate vaccines (PCV) in national immunization programs worldwide. However, PCV is not included in the National Immunization Program in China and has low vaccination coverage due to its high cost. To address this, Weifang City implemented an innovative strategy for a 13-valent PCV (PCV13) on June 1, 2021. This strategy aimed to provide one dose of PCV13 free of charge for children aged 6 months to 2 years in registered households and to adopt a commercial insurance model with one dose of PCV13 free of charge in 2023 for children over 2 years old. The Health Commission of Weifang and other departments conducted a comprehensive investigation and considered various factors, such as vaccine effectiveness, safety, accessibility, vaccine price, and immunization schedules, for eligible children (under 5 years old). Stakeholder opinions were also solicited before implementing the policy. The Commission negotiated with various vaccine manufacturers to maximize its negotiating power and reduce vaccine prices. The implementation plan was introduced under the Healthy Weifang Strategy. Following the implementation of this strategy, the full course of vaccination coverage increased significantly from 0.67 to 6.59%. However, vaccination coverage is still lower than that in developed countries. Weifang's PCV13 vaccination innovative strategy is the first of its kind in Chinese mainland and is an active pilot of non-immunization program vaccination strategies. To further promote PCV13 vaccination, Weifang City should continue to implement this strategy and explore appropriate financing channels. Regions with higher levels of economic development can innovate the implementation of vaccine programs, broaden financing channels, improve accessibility to vaccination services, and advocate for more localities to incorporate PCV13 into locally expanded immunization programs or people-benefiting projects. A monitoring and evaluation system should also be established to evaluate implementation effects. Graphical Abstract
- Published
- 2023
- Full Text
- View/download PDF
43. An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants
- Author
-
Shahrul Mt-Isa, Justin R. Chumbley, Emma L. Crawford, Natalie Banniettis, Ulrike K. Buchwald, Jessica Weaver, and Thomas Weiss
- Subjects
maic ,indirect treatment comparison ,pneumococcal conjugate vaccine ,immunoglobulin g ,immunogenicity ,pcv15 ,gmc ratio ,igg response rate ,Internal medicine ,RC31-1245 - Abstract
Objectives Immunogenicity between 15-valent V114 (PCV15) and 20-valent PCV20 pneumococcal conjugate vaccines in healthy infants is compared in an indirect treatment comparison and matching-adjusted indirect comparison. Hypotheses: immunogenicity of V114 is non-inferior to PCV20 for all PCV13 serotypes, and superior to PCV20 for serotype 3 based on lower bound margins. Methods Two phase 3 pivotal studies on 3 + 1 pediatric vaccination schedule at age 2, 4, 6, and 12–15 months compared V114 (N = 858) to PCV13 (N = 856) and PCV20 (N = 1001) to PCV13 (N = 987). Infant’s age and race in V114 study were matched to those in PCV20 study. Primary endpoints were serotype-specific Immunoglobulin G (IgG) response rate difference (RRD) 30 days post-dose (PD)3; IgG geometric mean concentration (GMC) ratios 30 days PD3 and PD4. Results V114 was non-inferior (${\rm{margi}}{{\rm{n}}_{RRD}}$>-10%-point; ${\rm{margi}}{{\rm{n}}_{GMCratio}}$ >0.5) to PCV20 (p-value 0%-point; ${\rm{margi}}{{\rm{n}}_{GMCratio}}$ >1.2) to PCV20 (p-value
- Published
- 2023
- Full Text
- View/download PDF
44. Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines
- Author
-
Michael Pichichero, Richard Malley, Ravinder Kaur, Robert Zagursky, and Porter Anderson
- Subjects
streptococcus pneumoniae ,pneumococcal conjugate vaccine ,acute otitis media ,epidemiology ,pneumococcal serotypes ,Internal medicine ,RC31-1245 - Abstract
Introduction Despite the introduction of effective pneumococcal conjugate vaccines (PCV), Streptococcus pneumoniae remains a major cause of acute otitis media (AOM) worldwide. New, higher valency vaccines that offer broader serotype coverage have been recently developed and others are in development. However, given the capsular serotypes expressed by pneumococci causing AOM, it is unclear to what extent differing or higher valency PCVs will provide additional protection. Areas Covered We conducted a systematic literature search of the MEDLINE database to identify articles published from January 2016 to September 2021 in 4 low and middle income and 10 high-income countries. We searched PubMed with terms: (Streptococcus pneumoniae) OR pneumococcal AND serotype AND (conjugate vaccine). We evaluated serotype distribution and the actual or projected coverage of pneumococcal serotypes by PCV10 (GlaxoSmithKline), PCV13 (Pfizer), PCV10SII (Serum Institute of India) PCV15 (Merck) and PCV20 (Pfizer). Expert Opinion Our review highlights the important epidemiological differences in serotype distribution and coverage by existing and higher valency vaccines to protect against AOM in children. These data provide support for further evaluation of serotype-independent vaccines for optimal control of pneumococcal AOM disease worldwide.
- Published
- 2023
- Full Text
- View/download PDF
45. A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom
- Author
-
James Campling, Andrew Vyse, Hui-Hsuan Liu, Hannah Wright, Mary Slack, Ralf-Rene Reinert, Mark Drayson, Alex Richter, Dave Singh, Gavin Barlow, George Kassianos, and Gillian Ellsbury
- Subjects
clinical risk group ,community acquired pneumonia ,epidemiology ,invasive pneumococcal disease ,pneumococcal conjugate vaccine ,pneumococcal polysaccharide vaccine ,vaccination guidelines ,vaccination uptake ,Internal medicine ,RC31-1245 - Abstract
Introduction Pneumococcal disease (PD) significantly contributes to morbidity and mortality, carrying substantial economic and public health burden. This article is a targeted review of evidence for pneumococcal vaccination in the UK, the definitions of groups at particular risk of PD and vaccine effectiveness. Areas covered Relevant evidence focusing on UK data from surveillance systems, randomized controlled trials, observational studies and publicly available government documents is collated and reviewed. Selected global data are included where appropriate. Expert opinion National vaccination programs have reduced the incidence of vaccine-type PD, despite the rising prominence of non-vaccine serotypes in the UK. The introduction of higher-valency conjugate vaccines provides an opportunity to improve protection against PD for adults in risk groups. Several incentives are in place to encourage general practitioners to vaccinate risk groups, but uptake is low-suboptimal particularly among at-risk individuals. Wider awareness and understanding among the public and healthcare professionals may increase vaccination uptake and coverage. National strategies targeting organizational factors are urgently needed to achieve optimal access to vaccines. Finally, identifying new risk factors and approaches to risk assessment for PD are crucial to ensure those at risk of PD can benefit from pneumococcal vaccination.
- Published
- 2023
- Full Text
- View/download PDF
46. The impact of pneumococcal conjugate vaccine on ceftriaxone consumption in the community among young children
- Author
-
Dana Danino, Bart Adriaan van der Beek, David Greenberg, Shalom Ben-Shimol, and Ron Dagan
- Subjects
Pneumococcal Conjugate Vaccine ,Ceftriaxone Consumption, Community, Children ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: Following pneumococcal conjugate vaccine (PCV) introduction, community pediatric dispensed prescription rates (DPR) of oral antibiotics declined, in parallel to respiratory tract infection (RTI). We assessed the dynamics of outpatient parenteral ceftriaxone DPR. Methods: Computerized data for children
- Published
- 2023
- Full Text
- View/download PDF
47. Prevention of Coronavirus Disease 2019 Among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions Between Streptococcus pneumoniae and Severe Acute Respiratory Syndrome Coronavirus 2 in the Respiratory Tract
- Author
-
Lewnard, Joseph A, Bruxvoort, Katia J, Fischer, Heidi, Hong, Vennis X, Grant, Lindsay R, Jódar, Luis, Gessner, Bradford D, and Tartof, Sara Y
- Subjects
Vaccine Related ,Pneumonia ,Infectious Diseases ,Lung ,Immunization ,Pneumonia & Influenza ,Prevention ,Infection ,Good Health and Well Being ,Aged ,Anti-Bacterial Agents ,COVID-19 ,COVID-19 Testing ,Humans ,Pneumococcal Infections ,Pneumococcal Vaccines ,Respiratory System ,SARS-CoV-2 ,Streptococcus pneumoniae ,Vaccines ,Conjugate ,pneumococcal conjugate vaccine ,older adults ,polymicrobial infection ,Streptococcus pneumoniae ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundWhile secondary pneumococcal pneumonia occurs less commonly after coronavirus disease 2019 (COVID-19) than after other viral infections, it remains unclear whether other interactions occur between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Streptococcus pneumoniae.MethodsWe probed potential interactions between these pathogens among adults aged ≥65 years by measuring associations of COVID-19 outcomes with pneumococcal vaccination (13-valent conjugate vaccine [PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPSV23]). We estimated adjusted hazard ratios (aHRs) using Cox proportional hazards models with doubly robust inverse-propensity weighting. We assessed effect modification by antibiotic exposure to further test the biologic plausibility of a causal role for pneumococci.ResultsAmong 531 033 adults, there were 3677 COVID-19 diagnoses, leading to 1075 hospitalizations and 334 fatalities, between 1 March and 22 July 2020. Estimated aHRs for COVID-19 diagnosis, hospitalization, and mortality associated with prior PCV13 receipt were 0.65 (95% confidence interval [CI], .59-.72), 0.68 (95% CI, .57-.83), and 0.68 (95% CI, .49-.95), respectively. Prior PPSV23 receipt was not associated with protection against the 3 outcomes. COVID-19 diagnosis was not associated with prior PCV13 within 90 days following antibiotic receipt, whereas aHR estimates were 0.65 (95% CI, .50-.84) and 0.62 (95% CI, .56-.70) during the risk periods 91-365 days and >365 days, respectively, following antibiotic receipt.ConclusionsReduced risk of COVID-19 among PCV13 recipients, transiently attenuated by antibiotic exposure, suggests that pneumococci may interact with SARS-CoV-2.
- Published
- 2022
48. National Bacterial Meningitis Study
- Author
-
Pfizer
- Published
- 2022
49. Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
- Published
- 2022
50. Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial.
- Author
-
Riekkinen, Marianna, Pakkanen, Sari H., Hutse, Veronik, Roukaerts, Inge, Ollgren, Jukka, Käyhty, Helena, Herzog, Christian, Rombo, Lars, and Kantele, Anu
- Subjects
- *
HEPATITIS A vaccines , *PNEUMOCOCCAL vaccines , *VIRAL hepatitis , *VACCINE effectiveness , *RANDOMIZED controlled trials , *PNEUMOCOCCAL pneumonia , *IMMUNE response - Abstract
We explored the influence of coadministration on safety and immunogenicity of the most common travellers' vaccine hepatitis A (HepA) and the pneumococcal conjugate vaccine (PCV) increasingly used both at home and before travel. Volunteers aged ≥18 years (n = 305) were randomly assigned 1:1:1 into three groups receiving: 13-valent PCV (PCV13) + HepA, PCV13, or HepA. Anti-pneumococcal IgG concentrations, opsonophagocytic activity (OPA) titres, and total hepatitis A antibody (anti-HAV) concentrations were measured before and 28 ± 3 days after vaccination. Adverse events (AEs) were recorded over 4 weeks. After vaccination, the anti-HAV geometric mean concentration was significantly lower in the PCV13+HepA than the HepA group: 34.47 mIU/mL (95% CI: 26.42–44.97 mIU/mL) versus 72.94 mIU/mL (95% CI: 55.01–96.72 mIU/mL), p < 0.001. Anti-HAV ≥10 mIU/mL considered protective was reached by 71 of 85 (83.5%) in the PCV13+HepA group versus 76 of 79 (96.2%) in the HepA group, p 0.008. The increases in anti-pneumococcal IgG and OPA levels were comparable in the PCV13+HepA and PCV13 groups, apart from a bigger rise in the PCV13+HepA group for serotype 3 (one-way ANOVA: serotype 3 IgG p 0.010, OPA p 0.002). AEs proved more frequent among those receiving PCV13 than HepA, but simultaneous administration did not increase the rates: ≥one AE was reported by 45 of 56 (80.4%) PCV13, 43 of 54 (79.6%) PCV13+HepA, and 25 of 53 (47.2%) HepA recipients providing structured AE data. Coadministration of HepA and PCV13 did not cause safety concerns, nor did it impact the patients' response to PCV13, apart from serotype 3. However, coadministered PCV13 significantly impaired antibody responses to HepA. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.